Mankind Pharma Ventures Into Feline Nutrition Market With Introduction Of Petstar Delight Product Line – BW Healthcare World
Mankind Pharma, a leading pharmaceutical company, has announced its expansion into the cat nutrition market with the launch of its Petstar Delight range. This move marks the company’s entry into the pet care industry, specifically targeting the growing demand for high-quality cat food. The Petstar Delight range is designed to provide cats with a nutritious and delicious diet, catering to their unique needs and preferences.
The Petstar Delight range includes a variety of products, such as dry food, wet food, and treats, all formulated to meet the nutritional requirements of cats at different life stages. The products are made with high-quality protein sources, including chicken, salmon, and lamb, and are free from artificial preservatives and flavors. The range also includes grain-free and gluten-free options, catering to cats with dietary sensitivities.
Mankind Pharma’s entry into the pet care industry is a strategic move, given the growing trend of pet humanization and the increasing demand for premium pet food. The company aims to leverage its expertise in pharmaceuticals to create high-quality pet food products that meet the evolving needs of cat owners. The Petstar Delight range is expected to be competitive in the market, offering a unique blend of nutrition, taste, and affordability.
The launch of Petstar Delight is also expected to create new opportunities for Mankind Pharma, allowing the company to tap into the rapidly growing pet care market. The global pet food market is projected to reach $180 billion by 2025, driven by increasing pet ownership and the rising demand for premium pet food. Mankind Pharma’s expansion into this market is likely to contribute to the company’s growth and diversification strategy.
The Petstar Delight range will be available across various channels, including online platforms, pet stores, and veterinary clinics. Mankind Pharma has also planned a comprehensive marketing campaign to promote the brand and create awareness about the importance of providing high-quality nutrition to cats. With the launch of Petstar Delight, Mankind Pharma is poised to become a significant player in the cat nutrition market, offering cat owners a reliable and trustworthy brand that prioritizes their pets’ health and well-being.
Cipla collaborates with Stempeutics to introduce revolutionary stem cell treatment for osteoarthritis of the knee.
Cipla, a leading pharmaceutical company, has partnered with Stempeutics, a stem cell therapy company, to launch a stem cell-based treatment for knee osteoarthritis in India. This innovative therapy aims to provide relief to patients suffering from knee osteoarthritis, a degenerative joint disease that affects millions of people worldwide.
Knee osteoarthritis is a common condition that causes pain, stiffness, and limited mobility in the knee joint. Current treatment options, such as painkillers, physical therapy, and surgery, often provide only temporary relief and can have significant side effects. Stem cell therapy, on the other hand, offers a promising alternative by using the body’s own cells to repair and regenerate damaged tissues.
The stem cell therapy launched by Cipla and Stempeutics uses mesenchymal stem cells, which are derived from the patient’s own bone marrow or adipose tissue. These cells have the ability to differentiate into various cell types, including cartilage cells, and can help repair damaged tissues in the knee joint. The therapy involves a simple, minimally invasive procedure, where the stem cells are injected into the affected knee joint.
According to the companies, this stem cell therapy has shown promising results in clinical trials, with significant improvements in pain reduction, functional ability, and quality of life. The therapy is also said to be safe, with minimal side effects reported.
The partnership between Cipla and Stempeutics marks a significant milestone in the field of regenerative medicine in India. Cipla’s extensive distribution network and marketing capabilities will help make this innovative therapy accessible to a wider audience, while Stempeutics’ expertise in stem cell technology will ensure the highest quality of the therapy.
The launch of this stem cell therapy is expected to revolutionize the treatment of knee osteoarthritis in India, providing new hope to patients who have been suffering from this debilitating condition. With its potential to repair and regenerate damaged tissues, this therapy may also reduce the need for surgical interventions and improve the overall quality of life for patients. As the field of regenerative medicine continues to evolve, partnerships like this one between Cipla and Stempeutics are likely to play a significant role in shaping the future of healthcare in India.
Aurobindo Group embarks on massive infrastructure development, transforming Kakinada port and SEZ into a thriving industrial and logistics hub.
The Aurobindo Group, a leading Indian conglomerate, has announced a major infrastructure development project to transform the Kakinada port and surrounding areas into a thriving industrial-logistics hub. The project, which is expected to be one of the largest of its kind in the country, aims to create a world-class infrastructure that will cater to the growing demands of various industries, including pharmaceuticals, petrochemicals, and manufacturing.
The Aurobindo Group has plans to develop a Special Economic Zone (SEZ) in the area, which will provide a conducive environment for businesses to set up and operate. The SEZ will offer state-of-the-art infrastructure, including roads, utilities, and logistics facilities, making it an attractive destination for investors. The group has already acquired a significant amount of land for the project and has begun construction work on the SEZ.
The development of the Kakinada port is a crucial aspect of the project. The port, which is currently a minor port, will be upgraded to a major port, with the capacity to handle large vessels and cargo. The port will be equipped with modern facilities, including cranes, warehouses, and container terminals, making it a major hub for trade and commerce in the region.
The Aurobindo Group’s project is expected to have a significant impact on the local economy, creating thousands of jobs and generating revenue for the state government. The project will also contribute to the growth of the Indian economy, by providing a boost to the manufacturing and logistics sectors. The group has estimated that the project will attract investments of over Rs 10,000 crore and create employment opportunities for over 50,000 people.
The project is also expected to have a positive impact on the environment, as it will promote the use of green technologies and sustainable practices. The Aurobindo Group has committed to using renewable energy sources, such as solar and wind power, to meet the energy requirements of the SEZ and port.
Overall, the Aurobindo Group’s mega infrastructure project in Kakinada is a significant development that is expected to transform the region into a major industrial-logistics hub. The project has the potential to create a positive impact on the local economy, environment, and the Indian economy as a whole. With its commitment to sustainable practices and world-class infrastructure, the project is expected to set a new standard for infrastructure development in the country.
Zydus’s injectable facility in Vadodara receives a U.S. FDA inspection report with a Voluntary Action Indicated (VAI) status.
The U.S. Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) to Zydus Lifesciences, an injectable facility based in Vadodara, India. The report, which was issued with a Voluntary Action Indicated (VAI) classification, is a result of a Good Manufacturing Practice (GMP) follow-up inspection conducted by the U.S. FDA at the facility from August 25 to September 5, 2025.
The VAI classification indicates that while the FDA has identified certain deficiencies or issues during the inspection, the company is not required to take immediate corrective action. Instead, the company is expected to voluntarily address the identified issues and implement corrective measures to ensure compliance with FDA regulations.
This inspection was a follow-up to a warning letter issued by the U.S. FDA to Zydus Lifesciences on August 29, 2024. The warning letter had highlighted certain deficiencies and violations of FDA regulations, and the recent inspection was conducted to assess the company’s progress in addressing these issues.
The fact that the FDA has issued an EIR with a VAI classification suggests that Zydus Lifesciences has made some progress in addressing the deficiencies identified in the warning letter. However, the company still needs to take further corrective action to ensure full compliance with FDA regulations.
The inspection and subsequent EIR are significant for Zydus Lifesciences, as they highlight the importance of maintaining high standards of quality and compliance in the pharmaceutical industry. The company must now take steps to address the identified issues and implement measures to prevent similar deficiencies from arising in the future.
Overall, the issuance of the EIR with a VAI classification is a positive step for Zydus Lifesciences, as it indicates that the company is on the path to resolving the issues identified by the FDA. However, the company must continue to work towards ensuring full compliance with FDA regulations to maintain its reputation and ensure the quality of its products.
Hospitals are experiencing a significant change in their revenue streams, with oncology emerging as the most lucrative department.
India’s top hospital chains, including Max Healthcare, Apollo Hospitals, and Fortis Healthcare, are experiencing a significant shift in their revenue mix, with oncology emerging as the fastest-growing and most profitable specialty. Oncology, once a niche segment, is now a central part of their strategic plans, driven by rising cancer incidence, improved diagnostics, and high-complexity treatments that command premium pricing.
At Max Healthcare, oncology contributes nearly 25% of inpatient revenue, making it the largest therapeutic segment. Fortis Healthcare reported a 28% year-on-year growth in oncology revenue in Q1 FY26, with the segment accounting for 16.4% of total hospital income. Apollo Hospitals, which pioneered proton therapy in India, sees oncology as both a clinical and commercial imperative, operating 13 Comprehensive Cancer Centres across 12 cities.
The growth in oncology is underpinned by factors such as rising cancer incidence, improved screening, insurance penetration, and the inherently high revenue per patient. Cancer care typically involves multidisciplinary teams, advanced diagnostics, and long treatment cycles, making it a high-margin specialty. According to the National Cancer Registry Programme Report 2020, the number of cancer cases in 2020 was estimated to be 13.9 lakhs, and it is projected to increase to 15.7 lakhs by 2025.
Hospitals are investing heavily in infrastructure, including expensive radiation therapy, robotic surgery machines, and advanced diagnostics. The demand for oncology services is strong, with LINAC utilization rising to 69% at HCG, reflecting the growing need for cancer care. As insurance penetration improves, more patients can afford advanced oncology procedures, further fueling demand.
The convergence of clinical need and commercial opportunity is making oncology the centerpiece of growth strategies for India’s leading hospital chains. With its high revenue potential and growing demand, oncology is expected to continue driving growth for these hospitals in the coming years. As Abhay Soi, Chairman and MD of Max Healthcare, said, “Oncology clearly is growing faster for us,” and hospitals are making significant investments in radiation oncology infrastructure to meet the growing demand.
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and patient comfort. The Drugs Controller General of India (DCGI) has given Sun Pharma permission for a large-scale clinical trial to test its semaglutide tablets, while Lupin has received the green light for its bioequivalence study.
Obesity is becoming a significant public health challenge in India, with a projected 450 million overweight and obese adults by 2050. Experts believe that the injectable form of semaglutide is more effective for weight loss, but the oral variant could improve accessibility and patient comfort. Other Indian companies, such as Dr. Reddy’s Laboratories Ltd, Cipla Ltd, and Mankind Pharma, are also developing generic versions of semaglutide.
The development of these anti-obesity drugs is significant, and experts urge strict medical supervision and caution against misuse. Dr. Balram Bhargava, former director general of the Indian Council of Medical Research (ICMR), said that these drugs are “wonder drugs and novel inventions” but should be used under strict medical supervision. He added that irrational use of these drugs could have serious consequences and that they are suitable as a second line of treatment for individuals who are obese and diabetic.
The key takeaways from this development are:
1. Sun Pharma and Lupin are developing oral semaglutide pills to address obesity and injection aversion.
2. Regulatory approvals have been granted for Phase III trials and bioequivalence studies.
3. India faces an obesity burden of 450 million adults by 2050.
4. Experts urge strict medical supervision and caution against misuse.
5. Generic versions may flood the market next year, reshaping affordability and access.
Overall, the development of oral semaglutide pills and the upcoming availability of generic versions could significantly impact the treatment of obesity in India. However, it is crucial to ensure that these drugs are used responsibly and under strict medical supervision to avoid misuse and potential consequences.
Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.
Sun Pharmaceutical Industries, a prominent pharmaceutical company, has faced a setback in its attempt to secure approval from the Central Drugs Standard Control Organisation (CDSCO) for a bioequivalence (BE) study and Phase III clinical trial waiver for its fixed-dose combination (FDC) drug containing sitagliptin, glimepiride, and metformin.
The CDSCO, India’s drug regulatory agency, has denied the waiver, which means that Sun Pharma will now have to conduct a full Phase III clinical trial to demonstrate the safety and efficacy of the FDC drug. This decision is likely to delay the launch of the drug in the Indian market.
The FDC drug in question combines three established anti-diabetic medications: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor; glimepiride, a sulfonylurea; and metformin, a biguanide. The combination of these drugs is intended to provide a convenient and effective treatment option for patients with type 2 diabetes.
The BE study and Phase III clinical trial waiver are crucial steps in the regulatory approval process for new drugs in India. The BE study is designed to demonstrate that the generic version of a drug is equivalent to the branded version in terms of pharmacokinetic and pharmacodynamic parameters. The Phase III clinical trial is a pivotal study that evaluates the safety and efficacy of a drug in a large population of patients.
Sun Pharma’s failure to secure the CDSCO nod for the BE study and Phase III waiver may be due to various reasons, including concerns about the safety and efficacy of the FDC drug or the adequacy of the data submitted by the company. The company will now have to conduct a full Phase III clinical trial, which will involve significant time, effort, and resources.
The setback is likely to impact Sun Pharma’s business plans and revenue projections for the FDC drug. However, the company can still pursue the development and launch of the drug in other markets, including the United States and Europe, where the regulatory requirements may be different. The company will have to re-strategize and re-submit its application to the CDSCO, addressing the concerns and objections raised by the regulator.
Immersion ceremony of Lord Ganesh and food donation completed at Apollo Hospital premises.
On September 7, 2025, in Hyderabad, Telangana, a significant event took place at Apollo Hospitals, located in Jubilee Hills. An 8-foot tall Ganesh idol was installed within the hospital premises, marking the beginning of a festive period. The idol was worshipped with great devotion and fervor by the hospital staff, patients, and devotees.
To further enhance the spirit of togetherness and joy, an Annadhanam, which is a sacred ritual of offering food to all, was organized. This act of sharing meals took place throughout the 11-day celebration, fostering a sense of community and harmony among all participants. The event aimed to bring people together, promoting unity and celebration during the festive season.
The culmination of the festivities occurred on Saturday, September 6, 2025, when the Ganesh idol was taken out in a grand procession. The procession was well-attended by a large number of staff members and devotees, who came together to bid farewell to the idol. Following the procession, the idol was immersed in water, marking the end of the 11-day celebration.
The immersion ceremony is a significant part of the Ganesh festival, symbolizing the return of Lord Ganesha to his heavenly abode. The event was marked by enthusiasm and devotion, with participants expressing their gratitude and seeking blessings from the deity. The successful organization of the event at Apollo Hospitals, Jubilee Hills, reflects the hospital’s commitment to fostering a sense of community and promoting cultural values among its staff and patients.
Overall, the installation and worship of the 8-foot tall Ganesh idol at Apollo Hospitals, Jubilee Hills, along with the Annadhanam and the grand procession, contributed to a festive atmosphere, promoting unity, joy, and togetherness among all participants. The event served as a reminder of the significance of cultural celebrations in bringing people together and fostering a sense of community.
Punjab’s Chief Minister is exhibiting signs of improvement while being closely monitored at Fortis Hospital.
Punjab Chief Minister Bhagwant Mann was admitted to Fortis Hospital in Mohali on Friday evening due to exhaustion and a low heart rate. The 51-year-old leader has been showing improvement, with stable vital signs and gradually improving blood parameters, according to hospital authorities. Mann was visited by several senior Aam Aadmi Party (AAP) leaders and Punjab cabinet ministers, including Manish Sisodia, Harpal Singh Cheema, Aman Arora, Gurmeet Singh Khuddian, and Sanjeev Arora.
Sisodia, who met with Mann, stated that the Chief Minister had been unwell for the past 2-3 days due to an electrolyte imbalance. However, he assured that Mann is currently fine and there is nothing to worry about. According to Sisodia, the doctors predict that Mann will remain in the hospital for one or two more days. The meeting of the Punjab cabinet, which was scheduled to be chaired by Mann, was postponed on Friday due to his illness.
Mann was also unable to accompany AAP national convener Arvind Kejriwal on a visit to flood-affected areas on Thursday. Kejriwal visited Mann at his official residence on Thursday to enquire about his health. This is not the first time Mann has been treated at Fortis Hospital, as he was admitted about a year ago for a bacterial infection.
The hospital authorities continue to monitor Mann’s condition, and his improvement is a positive sign. The visit from senior AAP leaders and cabinet ministers demonstrates the concern and support for the Chief Minister’s health. With Sisodia’s assurance that Mann is fine and will likely be discharged in a few days, it appears that the situation is under control. However, the exact nature of Mann’s illness and the expected duration of his hospital stay remain uncertain. As the situation develops, further updates on the Chief Minister’s health are expected to be released.
Aurobindo Pharma’s Unit-XII received eight observations.
Aurobindo Pharma, a prominent pharmaceutical company, recently underwent a USFDA (United States Food and Drug Administration) inspection at its Unit-XII facility. The inspection resulted in the issuance of 8 observations, which are essentially a list of deficiencies or areas that require improvement. These observations are a critical aspect of the USFDA’s inspection process, as they highlight specific concerns or non-compliances with regulatory standards.
The USFDA inspection is a rigorous evaluation of a pharmaceutical facility’s adherence to current Good Manufacturing Practices (cGMPs) and other regulatory requirements. The inspection team assesses various aspects of the facility, including its quality control systems, manufacturing processes, and overall compliance with FDA regulations. The issuance of 8 observations at Aurobindo Pharma’s Unit-XII facility indicates that the USFDA inspectors identified several areas that require corrective action.
While the specific details of the observations have not been disclosed, they likely pertain to issues such as inadequate quality control procedures, insufficient documentation, or non-compliance with standard operating procedures (SOPs). The company will be required to respond to these observations and provide a corrective action plan to address the identified deficiencies. This plan will outline the steps the company will take to rectify the issues and prevent future non-compliances.
The receipt of 8 observations may have implications for Aurobindo Pharma’s business operations and reputation. The company may need to invest significant resources to address the identified issues and ensure compliance with regulatory requirements. Additionally, the observations may impact the company’s ability to supply products to the US market, at least until the issues are resolved.
It is worth noting that the USFDA inspection process is designed to ensure the quality and safety of pharmaceutical products. The issuance of observations is a common occurrence during FDA inspections, and many companies receive similar notices. Aurobindo Pharma will need to take prompt and effective action to address the observations and demonstrate its commitment to compliance with regulatory standards. By doing so, the company can maintain its reputation as a reliable and trustworthy pharmaceutical manufacturer.
Lupin’s Aurangabad facility receives two observations from the US Food and Drug Administration.
Lupin, a pharmaceutical company, has received two observations from the US Food and Drug Administration (USFDA) for its Aurangabad facility. The observations were made during a recent inspection of the facility, which is located in Maharashtra, India.
The USFDA conducts regular inspections of pharmaceutical facilities to ensure compliance with current good manufacturing practices (cGMP) regulations. These regulations are in place to ensure the quality, safety, and efficacy of drugs manufactured for the US market. During an inspection, the USFDA may issue observations, also known as Form 483 observations, if it identifies any deviations from cGMP regulations.
The two observations issued to Lupin’s Aurangabad facility are related to specific aspects of its manufacturing operations. Although the exact nature of the observations has not been disclosed, they are likely related to issues such as equipment calibration, cleaning and sanitation, or documentation practices.
Receiving observations from the USFDA can have significant implications for a pharmaceutical company. If the observations are not addressed promptly and effectively, the company may face regulatory action, including a warning letter or even a import ban.
Lupin has stated that it is taking the observations seriously and is working to address the issues identified by the USFDA. The company has a robust corrective action plan in place, which includes corrective and preventive actions to ensure compliance with cGMP regulations. Lupin is committed to maintaining the highest standards of quality and compliance at all its facilities, including the Aurangabad facility.
The receipt of USFDA observations is not uncommon in the pharmaceutical industry, and many companies receive observations during inspections. What is important is how the company responds to the observations and takes corrective action to prevent similar issues from arising in the future.
In this case, Lupin’s prompt response and commitment to addressing the observations demonstrate its dedication to quality and compliance. The company will likely work closely with the USFDA to ensure that all issues are resolved and that its Aurangabad facility is compliant with cGMP regulations.
Overall, the receipt of USFDA observations for Lupin’s Aurangabad facility highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry. By addressing the observations promptly and effectively, Lupin can ensure the continued quality and safety of its products and maintain its reputation as a trusted pharmaceutical company.
Appeals court upholds former Pfizer employee’s guilty verdict for insider trading
A former Pfizer Inc. statistician has had his insider trading conviction affirmed by the Second Circuit. The individual was found guilty of making $272,000 in options trades using nonpublic information about the success of trials for the COVID-19 therapy drug Paxlovid. The conviction was upheld despite the defendant’s arguments that prosecutors had improperly changed their legal theory during the trial and had pursued the case in the wrong venue.
The Second Circuit’s decision confirms that the defendant’s actions constituted insider trading, and that he had used confidential information to make lucrative trades. The case highlights the importance of maintaining confidentiality and adhering to insider trading laws, particularly in the pharmaceutical industry where access to sensitive information can be highly valuable.
The defendant’s arguments that prosecutors had shifted their legal theory during the trial were rejected by the Second Circuit. The court found that the prosecution’s theory had been consistent throughout the trial, and that the defendant had been given adequate notice of the charges against him. Additionally, the court rejected the defendant’s argument that the case had been pursued in the wrong venue, finding that the prosecution had properly established jurisdiction.
The conviction serves as a reminder of the severe consequences of insider trading, and the importance of complying with securities laws. The case also underscores the need for pharmaceutical companies to maintain robust confidentiality protocols and to ensure that employees with access to sensitive information are aware of their obligations under insider trading laws.
The Second Circuit’s decision is significant, as it upholds the integrity of the securities markets and reinforces the importance of fair play in the trading of securities. The conviction of the former Pfizer statistician sends a strong message that insider trading will not be tolerated, and that those who engage in such activities will be held accountable. The decision is also a testament to the effectiveness of the legal system in detecting and punishing insider trading, and in maintaining the trust and confidence of investors in the securities markets.
Apollo Hospitals achieves success – News Today
In a significant medical achievement, Apollo Hospitals in Chennai has successfully performed India’s first implantation of the Edwards SAPIEN 3 Ultra RESILIA transcatheter aortic valve (TAVI) on a 70-year-old patient. The patient, who suffered from severe aortic stenosis and had a prior coronary stent, was deemed too high-risk for open-heart surgery. The procedure was led by Dr. G. Sengottuvelu, a senior interventional cardiologist and head of structural interventions.
The innovative RESILIA valve is designed to provide longer durability, resist calcification, and minimize the need for repeat surgeries. This cutting-edge technology offers a safer and more minimally invasive treatment option for patients with severe heart valve disease. According to Ms. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals Group, this breakthrough allows Indian patients to access advanced global technology with proven durability and improved long-term outcomes.
The RESILIA valve has been shown to reduce key risks associated with traditional valve replacement, including structural valve deterioration and paravalvular leak. Dr. Sengottuvelu noted that this marks a new chapter in cardiac care in India, providing patients with a more durable and effective treatment option. Clinical studies have demonstrated that the valve has over 99% freedom from deterioration at eight years, making it one of the most durable options available worldwide.
This milestone procedure highlights the commitment of Apollo Hospitals to providing innovative and cutting-edge medical treatment to patients in India. The introduction of the RESILIA valve is expected to significantly improve the treatment outcomes for patients with severe heart valve disease, offering them a safer and more effective alternative to traditional open-heart surgery. With its proven durability and minimal invasive approach, the RESILIA valve is poised to revolutionize the field of cardiac care in India.
Punjab Chief Minister Bhagwant Mann’s condition worsens, hospitalized at Fortis Mohali
Punjab Chief Minister Bhagwant Mann has been admitted to Fortis Hospital in Mohali due to health concerns. According to reports, Mann complained of exhaustion and a low heart rate, prompting his hospitalization. The news has led to the postponement of a scheduled Cabinet meeting to discuss the ongoing flood situation in the state.
Mann’s health issues have raised concerns, and he is currently undergoing treatment at the hospital. The exact nature of his condition is not yet clear, but his symptoms suggest that he may be experiencing fatigue and cardiovascular issues. The hospitalization has also led to changes in the schedule of other political events, including a visit by Delhi Chief Minister Arvind Kejriwal to flood-affected areas in Punjab.
Kejriwal, who is also the national convener of the Aam Aadmi Party (AAP), toured the flood-hit regions of Punjab, assessing the damage and meeting with affected residents. However, Mann was unable to accompany him due to his health issues. The AAP leader’s visit was seen as an attempt to show solidarity with the people of Punjab and to highlight the need for relief efforts.
The flood situation in Punjab remains a major concern, with many areas still underwater and thousands of people displaced. The state government has been working to provide relief and rehabilitation to those affected, but the task is daunting. The postponement of the Cabinet meeting has delayed discussions on the flood situation, and it is unclear when the meeting will be rescheduled.
Mann’s health issues have added to the challenges facing the Punjab government, which is already dealing with the aftermath of the floods. The hospitalization of the Chief Minister has raised concerns about the stability of the government and the impact on its ability to respond to the flood crisis. As the situation continues to unfold, it remains to be seen how the government will address the challenges ahead and provide relief to those affected by the floods.
Aurobindo’s Telangana facility receives Form 483 from USFDA, citing eight major observations.
The US Food and Drug Administration (FDA) recently conducted an inspection of a manufacturing facility in India. The facility, known as Unit-XII, is owned by a Hyderabad-based drug firm and is located in Bachupally, Telangana. The inspection took place from August 25 to September 5.
Unit-XII is a significant facility for the company, as it includes both oral solids and injectable manufacturing units. The FDA inspection was likely a routine evaluation to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) and other regulatory standards.
The Hyderabad-based drug firm made the announcement of the FDA inspection in a regulatory filing. The filing did not provide detailed information about the inspection, such as any findings or observations made by the FDA. However, the fact that the inspection was conducted suggests that the company is engaged in exporting pharmaceutical products to the US market.
The US FDA is responsible for regulating the safety and efficacy of pharmaceutical products in the US. As part of its oversight, the agency conducts regular inspections of manufacturing facilities, both domestic and foreign, to ensure compliance with regulatory standards. These inspections can be lengthy and thorough, involving a review of the facility’s processes, procedures, and quality control systems.
The outcome of the FDA inspection is not yet known, and it may take several weeks or even months for the agency to issue a report or take any regulatory action. If the inspection reveals any significant deficiencies or violations, the company may be required to take corrective action to address these issues.
The FDA inspection of Unit-XII is significant, as it reflects the growing importance of India’s pharmaceutical industry in the global market. India is one of the largest exporters of pharmaceutical products to the US, and many Indian companies have established a significant presence in the US market. The inspection also highlights the need for Indian pharmaceutical companies to maintain high standards of quality and compliance to ensure continued access to the US market.
Overall, the FDA inspection of Unit-XII is a routine evaluation that is part of the agency’s oversight of pharmaceutical manufacturing facilities. While the outcome of the inspection is not yet known, it is likely to have significant implications for the company and the Indian pharmaceutical industry as a whole.
Alkem Laboratories (NSE:ALKEM) appears to be in a strong position to handle its debt obligations.
Warren Buffett’s quote, “Volatility is far from synonymous with risk,” highlights the importance of considering debt when assessing a company’s risk. Alkem Laboratories Limited (NSE:ALKEM) carries debt, but the question remains whether this debt makes the company risky. To determine this, it’s essential to consider the company’s cash and debt together. As of March 2025, Alkem Laboratories had ₹13.8b in debt, which is offset by ₹41.0b in cash, resulting in ₹27.2b in net cash.
The company’s balance sheet shows that it has ₹39.6b in liabilities due within a year and ₹12.9b due beyond that. However, it also has ₹41.0b in cash and ₹25.9b in receivables due within a year, resulting in ₹14.4b more liquid assets than total liabilities. This short-term liquidity indicates that Alkem Laboratories could easily pay off its debt, and its balance sheet is not stretched. The company’s net cash position and ability to convert earnings before interest and tax (EBIT) to free cash flow, which has been around 75% over the last three years, put it in a good position to manage its debt.
Alkem Laboratories’ debt does not appear to be a significant risk, given its net cash position and decent-looking balance sheet. The company’s ability to generate free cash flow and its growth in EBIT by 4.4% in the last year also make its debt load more manageable. While it’s always important to investigate a company’s debt, Alkem Laboratories’ situation does not seem to pose a significant risk. However, it’s essential to consider other factors, such as the company’s overall financial health and potential risks that may not be immediately apparent from the balance sheet.
In conclusion, Alkem Laboratories’ debt is not a significant concern, given its net cash position, ability to generate free cash flow, and decent-looking balance sheet. The company’s growth in EBIT and its ability to convert earnings to free cash flow also contribute to its relatively low-risk debt profile. However, it’s crucial to continue monitoring the company’s financial health and potential risks to ensure that its debt remains manageable.
Prohance D by Sun Pharma empowers individuals with diabetes to maintain an active lifestyle.
Sun Pharmaceutical Industries Limited, India’s leading pharmaceutical company, has launched a large-scale digital video campaign for Prohance D Diabetes Care, a nutritional supplement designed for individuals managing diabetes. The campaign, titled “Dekhta Hoon Nahi, Dikhata Hoon,” aims to address the emotional impact of diabetes on people’s lives, particularly the unpredictability of blood sugar levels that can make planning and living spontaneously challenging.
The campaign highlights how this unpredictability can lead to a life of “maybes” and hesitation, affecting not only daily routines but also relationships. The message is conveyed through a heartwarming story of a child who notices his father’s hesitation to commit to plans due to his diabetes and decides to help him. This narrative approach is a departure from the typical medicalized conversation in the diabetes category, instead focusing on the emotional truths of living with the condition.
By taking a more human approach, Prohance D aims to connect with its audience on a deeper level, emphasizing that better blood glucose management and prolonged energy can empower people with diabetes to live life to the fullest. The campaign, conceptualized by Curativity, Mumbai, reflects Sun Pharma’s belief that meaningful change begins with connection and understanding. Prohance D is positioned as a solution that can help individuals with diabetes move from uncertainty to action, embracing life’s plans and nurturing relationships.
The campaign’s focus on emotional storytelling and relatability is a strategic choice, as it allows Prohance D to stand out in a category often dominated by medical jargon and statistics. By emphasizing the human impact of diabetes and the benefits of better blood glucose management, Prohance D aims to resonate with its target audience and establish a strong connection with them. Overall, the campaign is a significant effort by Sun Pharma to promote Prohance D Diabetes Care and support individuals with diabetes in managing their condition and living a more fulfilling life.
Bringing Karnataka’s Artificial Intelligence Vision to Life
Elets Technomedia, in partnership with eGov magazine and the Department of Information Technology, Biotechnology, and Science & Technology of the Government of Karnataka, is set to release a unique souvenir magazine focused on Artificial Intelligence (AI) at the Bengaluru Tech Summit 2024. This special edition, dubbed the AI Souvenir Magazine, aims to put the spotlight on Karnataka’s most significant advancements and groundbreaking initiatives in the AI sector.
The magazine is tailored to showcase the state’s vision for the future, highlighting its commitment to leveraging AI and other cutting-edge technologies to drive innovation and progress. It will serve as a comprehensive guide, providing insights into Karnataka’s strategic plans, success stories, and the challenges it has overcome in its pursuit of becoming a leader in the tech industry.
By releasing this souvenir at the Bengaluru Tech Summit 2024, the organizers are creating a platform for stakeholders, including policymakers, industry leaders, and innovators, to come together and explore the vast potential of AI in transforming the state’s economy and society. The summit itself is poised to be a melting pot of ideas, with discussions ranging from the latest trends in AI to its applications across various sectors.
The AI Souvenir Magazine is an opportunity for Karnataka to present its achievements and ambitions on a global stage, attracting potential investors, partners, and talent to the state. It underscores the government’s proactive approach to embracing technology and its dedication to creating an ecosystem that fosters growth, innovation, and entrepreneurship.
In essence, the AI Souvenir Magazine is more than just a publication; it’s a testament to Karnataka’s forward-thinking approach and its determination to be at the forefront of the AI revolution. It promises to be a valuable resource for anyone interested in understanding the state’s strategy for harnessing the power of AI to propel its development and cement its position as a hub for technological excellence. Through this initiative, Karnataka is poised to reinforce its reputation as a state that is committed to innovation, progress, and the adoption of cutting-edge technologies.
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk’s blockbuster weight-loss drug, semaglutide, which is sold under the brand names Wegovy and Ozempic. Natco Pharma has filed six new patent-infringement lawsuits against Novo Nordisk, intensifying the legal challenge against the Danish drugmaker.
The Indian pharmaceutical companies are seeking to challenge Novo Nordisk’s patents on semaglutide, which has gained widespread popularity as a treatment for weight loss and diabetes. The lawsuits filed by Natco Pharma are the latest development in the ongoing patent battle between Novo Nordisk and Indian pharmaceutical companies.
This patent dispute has significant implications for the pharmaceutical industry, particularly in India, where generic drug manufacturers are seeking to produce affordable versions of semaglutide. If the Indian companies are successful in challenging Novo Nordisk’s patents, it could lead to the introduction of generic versions of semaglutide in the Indian market, potentially disrupting Novo Nordisk’s dominance in the market.
The patent battle is being closely watched by regulatory experts and pharmaceutical companies, as it has the potential to impact the availability and affordability of semaglutide in India. The outcome of the lawsuits will depend on the Indian courts’ interpretation of the patent laws and the validity of Novo Nordisk’s patents on semaglutide.
In related news, regulatory experts are highlighting the importance of staying ahead of regulatory changes, particularly in the pharmaceutical industry. With the increasing complexity of patent laws and regulatory requirements, companies need to be prepared to navigate these challenges to stay competitive. Experts recommend staying informed about regulatory developments and seeking predictive analysis from expert journalists to anticipate potential risks and opportunities.
Alkem Laboratories injects $70 million into the US market, leveraging its Enzene capabilities.
Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India’s top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move follows President Donald Trump’s calls to pharmaceutical companies to increase local manufacturing and create employment opportunities. Currently, the facility has hired 50 people, with plans to expand its workforce to 200 employees over time.
According to Himanshu Gadgil, CEO of Enzene Biosciences, the company has developed a connected continuous manufacturing technology, known as EnzeneX, which offers significant cost efficiencies and faster processing compared to traditional batch-wise biotech drug manufacturing. This technology has been developed indigenously by Enzene and is now being implemented in the US facility.
Gadgil sees this development as a reflection of Enzene’s growth and the strength of India’s scientific ecosystem. He believes that this technology has the potential to contribute transformative solutions to the world. The establishment of the US facility is a significant milestone for Enzene, marking its expansion into the global market.
The connected continuous manufacturing technology developed by Enzene is expected to revolutionize the biotech drug manufacturing process. By offering cost efficiencies and faster processing, this technology has the potential to increase the availability of biotech drugs and reduce their costs. The implementation of this technology in the US facility is expected to have a positive impact on the global biotech industry.
Overall, Enzene’s launch of its US manufacturing facility is a significant development in the biotech industry. The company’s investment in the US market and its commitment to developing innovative technologies are expected to drive growth and expansion in the years to come. With its strong foundation in India and its expanding presence in the global market, Enzene Biosciences is poised to become a major player in the biotech industry.
Glenmark Pharmaceuticals Inc., USA is set to introduce Eribulin Mesylate Injection in 1mg/2mL single-dose vials, with a concentration of 0.5 mg/mL.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc. The launch is scheduled to take place in September 2025.
According to IQVIA sales data, the Halaven Injection market achieved annual sales of approximately $66.3 million for the 12-month period ending July 2025. The company’s President and Business Head, North America, Marc Kikuchi, expressed his pleasure at the launch, stating that it marks the company’s commitment to growing its portfolio of products within the institutional channel and reinforces its dedication to providing quality and affordable alternatives to patients in need.
Glenmark’s Eribulin Mesylate Injection is only approved for the indications listed in the company’s approved label. The product will be distributed in the US market, and the company is confident that it will make a significant impact in the pharmaceutical industry.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence in branded, generics, and OTC segments. The company has a focus on therapeutic areas such as respiratory, dermatology, and oncology. It has 11 world-class manufacturing facilities spread across four continents and operations in over 80 countries.
The company has been ranked among the top 100 biopharmaceutical companies by Pharmaceutical Sales in 2023 and among the top 50 generics and biosimilar companies by sales in 2024. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved by the Science Based Target initiative (SBTi), making it the second pharmaceutical company in India to achieve this.
The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. With the launch of Eribulin Mesylate Injection, Glenmark Pharmaceuticals Inc., USA, aims to continue its mission of providing quality and affordable pharmaceutical products to patients in need.
The launch of this product is a significant milestone for the company, and it is expected to have a positive impact on the pharmaceutical industry. Glenmark’s commitment to providing quality and affordable alternatives to patients in need is evident in its dedication to growing its portfolio of products within the institutional channel.
As the company continues to expand its presence in the US market, it is likely to face competition from other pharmaceutical companies. However, with its strong portfolio of products and commitment to quality and affordability, Glenmark Pharmaceuticals Inc., USA, is well-positioned to make a significant impact in the industry.
In conclusion, the launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials, by Glenmark Pharmaceuticals Inc., USA, is a significant development in the pharmaceutical industry. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, and is expected to provide a quality and affordable alternative to patients in need.
Zydus Lifesciences introduces the country’s inaugural trivalent vaccine to combat Influenza in India.
The global market for seasonal influenza vaccines is expected to experience significant growth, with a projected value of $24.1 billion by 2035, up from $10.2 billion in 2025, at a compound annual growth rate (CAGR) of 9%. Major multinational vaccine manufacturers, such as GlaxoSmithKline, Sanofi, Seqirus, and AstraZeneca, produce trivalent flu vaccines under various brand names, including Fluarix, Flulaval, Fluzone, Fluad, and FluMist. These vaccines are commonly administered in the US and other Western countries to protect against seasonal influenza, a contagious respiratory illness caused by influenza viruses that spread through airborne respiratory droplets or direct contact.
Seasonal influenza viruses evolve rapidly, requiring annual updates to vaccine compositions. Global surveillance systems, such as the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), guide these updates. Recently, Zydus introduced a new vaccine, which is significant for India, as it aligns with global recommendations. Since March 2020, the influenza B Yamagata virus has not circulated in countries like India, leading global regulatory bodies, including the WHO and Centers for Disease Control and Prevention (CDC), to recommend its exclusion from vaccine formulations.
The introduction of new vaccines, such as the one from Zydus, is expected to contribute to the growth of the seasonal influenza vaccines market. The market’s expansion will also be driven by increasing awareness about the importance of vaccination, particularly in regions with limited access to healthcare services. As the global population becomes more aware of the risks associated with seasonal influenza, the demand for effective vaccines is likely to rise, driving the market’s growth. With the global pattern of influenza virus circulation continuously evolving, the development of new vaccines and updates to existing ones will remain crucial in protecting against this contagious respiratory illness.
Glenmark introduces the United States’ first complex generic cancer medication.
Glenmark Pharmaceuticals has made a significant breakthrough in the US market by launching the first complex generic cancer drug, Fulvestrant Injection, 250 mg/5 mL (50 mg/mL). This is a generic version of Faslodex, an injectable medication used to treat hormone receptor-positive metastatic breast cancer. The launch of this complex generic drug marks a major milestone for Glenmark, as it is the first company to introduce a generic version of this medication in the US.
Fulvestrant Injection is a complex drug that requires specialized manufacturing capabilities, making it a challenging but significant achievement for Glenmark. The company has demonstrated its expertise in developing and commercializing complex generics, and this launch underscores its commitment to providing affordable and high-quality medications to patients in the US.
The introduction of Glenmark’s Fulvestrant Injection is expected to provide significant savings to the US healthcare system, as it offers a more affordable alternative to the branded version. Breast cancer is a leading cause of cancer-related deaths among women, and the availability of affordable treatment options is crucial to improving patient outcomes.
Glenmark’s Fulvestrant Injection has been approved by the US Food and Drug Administration (FDA) and is available in a 250 mg/5 mL (50 mg/mL) strength. The medication is administered via injection and is used to treat hormone receptor-positive metastatic breast cancer in patients who have experienced disease progression after anti-estrogen therapy.
The launch of Fulvestrant Injection is a testament to Glenmark’s capabilities in developing complex generics and its dedication to providing innovative and affordable treatments to patients. The company’s expertise in oncology and its commitment to expanding its portfolio of complex generics are expected to drive growth and strengthen its position in the US market.
Glenmark’s entry into the complex generics space is likely to have a significant impact on the US pharmaceutical market. The company’s ability to develop and commercialize complex generics will provide patients with access to affordable and high-quality medications, ultimately driving better health outcomes. As the healthcare landscape continues to evolve, Glenmark’s focus on complex generics is expected to play a critical role in shaping the future of the pharmaceutical industry.
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India’s pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing significantly to the country’s pharmaceutical output. The North Gujarat region, in particular, accounts for 12% of the state’s pharmaceutical manufacturing, making it a crucial hub for the industry.
Mehsana is a notable location in North Gujarat, offering substantial prospects in bulk drug production, Active Pharmaceutical Ingredients (APIs), intermediates, and formulations. Torrent Pharma, a prominent company in the region, operates a USFDA-approved facility, producing insulin for Novo Nordisk, making it India’s sole contract manufacturer of insulin for the company. This highlights the region’s capabilities in producing high-quality pharmaceutical products.
Patan, another district in North Gujarat, is also making significant contributions to the pharmaceutical sector, with a strong base of micro, small, and medium enterprises (MSMEs) specializing in injectables and formulations. The district is also gaining traction in the MedTech sector, with companies producing vascular interventional devices and medical equipment, such as hospital trolleys. The region’s educational institutions support this growth, with a focus on healthcare and pharmaceutical education.
The region’s comprehensive healthcare network, comprising 318 Primary Health Centres and 75 Community Health Centres, provides robust healthcare services across government and private sectors. This network is expected to be further strengthened by the forthcoming Vibrant Gujarat Regional Conference (VGRC), which aims to foster collaboration among the government, industry, and academia. The conference is expected to have a significant impact on the pharmaceutical sector’s trajectory, driving growth and innovation in the region.
Overall, North Gujarat is poised to become a major hub for the pharmaceutical industry, driven by government support, investment opportunities, and a strong network of educational institutions and healthcare services. The region’s potential for growth and innovation is significant, and the forthcoming VGRC is expected to play a key role in shaping the sector’s future. With its strong foundation in pharmaceutical manufacturing, North Gujarat is well-positioned to contribute to India’s growing pharmaceutical industry.
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older. The company’s application is based on a study of over 2,200 children in this age group, which showed that a lower dose of the vaccine (one-third of the standard dose) was safe and effective in producing a strong immune response.
The study found that the lower dose of the vaccine produced similar antibody levels in children aged 5-11 as the standard dose produces in teenagers and adults. Pfizer reports that there were no serious side effects observed in the study, although it notes that the study was not large enough to detect extremely rare side effects.
If the FDA approves the application, vaccinations for children aged 5-11 could begin within a matter of weeks. However, there are additional steps that must be taken before vaccinations can start. An independent expert panel will review the evidence and debate it publicly on October 26, and the Centers for Disease Control and Prevention (CDC) will also need to weigh in and make a recommendation.
Many parents and pediatricians are eager for a vaccine to be available for younger children, as COVID-19 can still cause serious illness in this age group, and the virus has been spreading rapidly in communities with low vaccination rates. According to the CDC, COVID-19 cases in children have skyrocketed in recent months, particularly with the spread of the delta variant.
One child, Sebastian Prybol, 8, from Raleigh, North Carolina, is participating in Pfizer’s study at Duke University and is eager to see the vaccine approved. His mother, Britni Prybol, says she will be “overjoyed” if the FDA clears the vaccine, but emphasizes the importance of ensuring its safety for children. The approval of a vaccine for children aged 5-11 would be a significant step forward in the fight against COVID-19, and could help to reduce the spread of the virus in schools and communities.
Fortis Hospital in Mohali hosts the zonal finals of ‘PSYCH-ED 2025’
Fortis Hospital, Mohali, recently hosted the zonal finals of the 8th edition of its national psychology quiz program, “PSYCH-ED, 2025”. The event saw participation from over 900 schools across India, with more than 12,000 students from 190+ cities taking part in the online round. The quiz was designed for students in classes XI and XII, aiming to test their knowledge of psychology and its concepts. The program was supported by several organizations, including GD Goenka University, Project CACA, Rupa Publications, and Adayu, a Fortis group company.
The quiz has grown into a flagship national-level event, engaging schools from urban metros, small towns, and even overseas, creating an inclusive platform for learning and discussion. The objective of the quiz is to impart learning while making the discipline of psychology engaging and fun for students. According to Dr. Samir Parikh, Chairperson, Fortis National Mental Health Programme, the initiative aims to promote awareness, reduce stigma around mental health, and inspire curiosity about psychology among school students.
The winning team from Bal Bharti School, Ludhiana, consisting of Anaisha Sharma, Prabhdeep Kaur, and Tanya Singla, will move on to the national finals in Delhi. The team expressed their excitement and gratitude towards their psychology teacher, who helped them prepare for the quiz. The quiz serves as an engaging and enjoyable way to learn, blending education with fun. The program has been conceptualized and executed under the aegis of Dr. Parikh, who believes that initiatives like PSYCH-ED can help promote awareness and reduce stigma around mental health.
The success of PSYCH-ED 2025 demonstrates the growing interest in psychology among school students, and the need for such initiatives to promote awareness and education about mental health. With its inclusive platform and engaging format, PSYCH-ED has become a unique and valuable resource for students, teachers, and schools across India. As the program continues to grow and evolve, it is likely to have a positive impact on the way psychology is perceived and studied in Indian schools, and contribute to a greater understanding and awareness of mental health issues.
Zydus Wellness broadens international presence through strategic takeover of Comfort Click, a UK-based entity.
Zydus Wellness Limited has made its first international acquisition by purchasing Comfort Click Limited (CCL), a UK-based company specializing in vitamins, minerals, and supplements. The deal was completed by Zydus’s UK arm, Alidac UK Limited, on August 29. The acquisition gives Zydus a direct entry into the fast-growing VMS (Vitamins, Minerals, and Supplements) category. The deal was valued at 239 million pounds, with an additional profit-linked adjustment.
Comfort Click has a strong presence in the UK and Europe, and has also started building its presence in the US. The company reported revenues of 134 million pounds for the year ended June 2025, with a five-year compounded annual growth rate of 57%. Comfort Click operates three brands: WeightWorld, maxmedix, and Animigo, which offer plant-based nutrition, gummy-based products for children, and natural supplements for pets, respectively. Most of its sales come through e-commerce and direct-to-consumer channels.
The acquisition is part of Zydus’s strategy to expand its international footprint, strengthen its consumer health portfolio, and grow in areas such as digital health and personalized wellness. The company’s Chairman, Dr. Sharvil Patel, stated that the acquisition reflects the company’s commitment to building a stronger wellness portfolio. The deal is expected to empower consumers to make informed choices and embrace wellness-focused products.
The European VMS market, where Comfort Click is active, is estimated to be around 11 billion pounds. Comfort Click has been listed among the 1,000 fastest-growing businesses in Europe by the Financial Times in 2024 and 2025. The acquisition is not a related-party deal, and no promoter group has any stake in it. With this acquisition, Zydus Wellness Limited has taken a significant step into the global market, and is expected to continue its growth trajectory in the consumer health and wellness space.
The acquisition of Comfort Click Limited is a strategic move by Zydus Wellness Limited to expand its international presence and strengthen its consumer health portfolio. The deal is expected to bring significant benefits to Zydus, including access to new markets, products, and customers. With its strong brands and digital presence, Comfort Click is well-positioned to continue its growth trajectory, and Zydus is expected to leverage this acquisition to drive its own growth and expansion in the global market.
Piramal Pharma Solutions and George Medicines collaborate on Widaplik, a novel medication for treating hypertension.
Piramal Pharma Solutions and George Medicines have collaborated to develop a new drug for the treatment of hypertension, known as Widaplik. This development is a significant milestone in the pharmaceutical industry, as hypertension is a major health concern worldwide.
Widaplik is designed to provide an effective and safe treatment option for patients with hypertension. The drug has undergone rigorous clinical trials to ensure its efficacy and safety. The collaboration between Piramal Pharma Solutions and George Medicines has enabled the development of this innovative drug, which is expected to improve the quality of life for patients with hypertension.
Piramal Pharma Solutions is a leading global pharmaceutical company that offers a wide range of services, including drug development, manufacturing, and distribution. The company has a strong reputation for delivering high-quality pharmaceutical products and has a significant presence in the global market.
George Medicines is a pharmaceutical company that specializes in the development and commercialization of innovative medicines. The company has a strong focus on research and development and has a pipeline of promising new drugs in various stages of development.
The development of Widaplik is a testament to the collaboration and innovation between Piramal Pharma Solutions and George Medicines. The drug is expected to be available in the market soon, subject to regulatory approvals. The launch of Widaplik is expected to have a significant impact on the pharmaceutical industry, as it provides a new treatment option for patients with hypertension.
Hypertension is a major health concern worldwide, and the development of new treatments is crucial to improving patient outcomes. Widaplik has the potential to make a significant difference in the lives of patients with hypertension, and its development is a major achievement for Piramal Pharma Solutions and George Medicines.
The collaboration between Piramal Pharma Solutions and George Medicines demonstrates the importance of partnerships in the pharmaceutical industry. By working together, companies can leverage their expertise and resources to develop innovative new treatments that improve patient outcomes. The development of Widaplik is a shining example of the impact that collaboration and innovation can have on the pharmaceutical industry.
In conclusion, the development of Widaplik by Piramal Pharma Solutions and George Medicines is a significant milestone in the pharmaceutical industry. The drug has the potential to make a major difference in the lives of patients with hypertension, and its launch is expected to have a significant impact on the market. The collaboration between the two companies demonstrates the importance of partnerships in the pharmaceutical industry and highlights the potential for innovation and development in the treatment of hypertension.
Aurobindo Pharma’s Telangana facility receives 5 observations from the US Food and Drug Administration.
Aurobindo Pharma, a leading pharmaceutical company, has received five observations from the US Food and Drug Administration (USFDA) for its facility in Telangana, India. The observations were made during a recent inspection of the facility, which is a key manufacturing site for the company.
The USFDA inspection was conducted to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) regulations. The observations made by the USFDA are related to various aspects of the facility’s operations, including quality control, documentation, and manufacturing processes.
While the exact nature of the observations has not been disclosed, they are likely to be related to issues such as inadequate documentation, insufficient quality control measures, or non-compliance with standard operating procedures. The company has stated that it is taking immediate action to address the observations and rectify the issues.
Aurobindo Pharma has a strong track record of compliance with regulatory requirements and has made significant investments in its quality systems and manufacturing infrastructure. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the USFDA to resolve the issues.
The receipt of observations from the USFDA is not uncommon, and it is a normal part of the regulatory process. Many pharmaceutical companies receive observations during inspections, and it is an opportunity for them to identify areas for improvement and take corrective action.
Aurobindo Pharma has stated that it is confident that it can resolve the issues and regain compliance with USFDA regulations. The company is working closely with the regulatory agency to address the observations and implement corrective actions. The facility in Telangana is a key manufacturing site for the company, and it is essential that it is operating in compliance with regulatory requirements to ensure the quality and safety of its products.
Overall, the receipt of five observations from the USFDA is a setback for Aurobindo Pharma, but it is an opportunity for the company to identify areas for improvement and take corrective action. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the regulatory agency to resolve the issues. With its strong track record of compliance and commitment to quality, Aurobindo Pharma is confident that it can regain compliance with USFDA regulations and continue to produce high-quality products for its customers.
Zydus Wellness expands into UK and EU markets with the acquisition of UK-based company Comfort Click.
Zydus Wellness, an Indian consumer goods company, has made a significant move by acquiring Comfort Click, a UK-based company. This acquisition marks Zydus Wellness’s foray into the UK and EU markets, expanding its global presence.
The acquisition is a strategic move by Zydus Wellness to tap into the vast consumer market in the UK and EU. Comfort Click is a well-established company in the UK, and its acquisition will provide Zydus Wellness with a strong foothold in the region. The company plans to leverage Comfort Click’s existing distribution network and customer base to launch its own products in the UK and EU markets.
Zydus Wellness has a diverse portfolio of brands, including Sugar Free, EverYuth, and Nutralite, among others. The company is expected to introduce these brands in the UK and EU markets, where there is a growing demand for health and wellness products. The acquisition of Comfort Click will enable Zydus Wellness to tap into this demand and increase its global revenue.
The UK and EU markets offer a significant opportunity for Zydus Wellness to grow its business. The region has a large and diverse consumer base, with a high demand for health and wellness products. The company’s products, such as Sugar Free and EverYuth, are expected to resonate well with consumers in the UK and EU, who are increasingly looking for healthy and natural products.
The acquisition of Comfort Click is also expected to provide Zydus Wellness with access to new distribution channels and retail partners in the UK and EU. The company plans to use these channels to launch its products and increase its visibility in the region. Additionally, the acquisition will provide Zydus Wellness with valuable insights into the UK and EU markets, enabling it to develop products that cater to the specific needs of consumers in the region.
Overall, the acquisition of Comfort Click by Zydus Wellness is a significant development that marks the company’s entry into the UK and EU markets. The move is expected to drive growth and expansion for Zydus Wellness, and provide new opportunities for the company to increase its global revenue. With its diverse portfolio of brands and strong distribution network, Zydus Wellness is well-positioned to tap into the growing demand for health and wellness products in the UK and EU.
Mankind Pharma emerges victorious in PETKIND trademark dispute, court directs publication of advertisement in journal within 60-day timeframe
Mankind Pharma has recently emerged victorious in a trademark battle involving the PETKIND trademark. The court has ruled in favor of Mankind Pharma, ordering the opposing party to publish a journal advertisement within a period of two months.
The specifics of the trademark dispute and the court’s decision have not been detailed, but it can be inferred that Mankind Pharma successfully demonstrated its rights to the PETKIND trademark. This outcome highlights the importance of trademark protection and the measures companies must take to safeguard their intellectual property.
The court’s order for the opposing party to publish a journal advertisement acknowledging Mankind Pharma’s victory is a significant step. This move serves as a public declaration of the court’s decision, helping to inform the public and the business community about the outcome of the dispute. By doing so, it reinforces the legitimacy of Mankind Pharma’s claim to the PETKIND trademark and helps prevent potential confusion or misuse of the trademark by other parties.
The use of journal advertisements as a means of disseminating information about court decisions is not uncommon. It provides a formal and widely accessible platform for announcing the outcome of legal disputes, ensuring transparency and awareness among stakeholders. In this case, the journal advertisement will likely outline the key points of the court’s decision, reiterating Mankind Pharma’s rights to the PETKIND trademark and cautioning others against infringing upon these rights.
Mankind Pharma’s success in this trademark battle underscores the company’s commitment to protecting its intellectual property and maintaining its competitive edge in the market. The pharmaceutical industry is highly competitive, and trademarks play a crucial role in distinguishing one company’s products from another. By vigorously defending its trademarks, Mankind Pharma demonstrates its dedication to upholding its brand identity and reputation.
The outcome of this dispute also serves as a reminder to businesses of the importance of conducting thorough trademark searches and ensuring that their branding does not infringe upon existing trademarks. This proactive approach helps prevent costly legal battles and potential damage to a company’s reputation. As the pharmaceutical landscape continues to evolve, the ability to protect and enforce intellectual property rights will remain a vital aspect of a company’s overall strategy.
The U.S. Food and Drug Administration has issued five observations to an active pharmaceutical ingredient plant owned by Aurobindo Pharma’s subsidiary.
The US Food and Drug Administration (FDA) has conducted an inspection of an active pharmaceutical ingredients (API) manufacturing facility owned by Apitoria Pharma, a subsidiary of Aurobindo Pharma. The facility, located in the Sangareddy district near Hyderabad, was inspected from August 21 to 29. Following the inspection, the FDA issued a Form 483, which included five observations regarding the facility’s procedures.
According to Aurobindo Pharma, the observations made by the FDA are procedural in nature, and there were no issues related to data integrity reported. This suggests that the issues identified by the FDA are related to the facility’s operational procedures and do not involve any concerns about the accuracy or reliability of the data generated by the facility.
Aurobindo Pharma has stated that it will respond to the FDA’s observations within the stipulated timelines. The company did not provide any further details about the nature of the observations or the steps it plans to take to address them. The issuance of a Form 483 does not necessarily mean that the facility is in violation of FDA regulations, but rather that the agency has identified areas where the facility can improve its procedures to ensure compliance with regulatory standards.
The inspection and subsequent issuance of a Form 483 are part of the FDA’s ongoing efforts to ensure that pharmaceutical manufacturing facilities, including those located outside the US, comply with its regulations and standards. Aurobindo Pharma is a major pharmaceutical company with a significant presence in the global market, and the outcome of this inspection could have implications for the company’s operations and reputation.
It is worth noting that the FDA’s inspection and observation process is designed to be transparent and collaborative, with the goal of ensuring that pharmaceutical manufacturing facilities operate in a way that prioritizes public health and safety. Aurobindo Pharma’s response to the FDA’s observations will be closely watched by regulators, investors, and other stakeholders, and the company’s ability to address the issues identified by the FDA will be an important factor in determining the outcome of this situation.
Zydus prepares US regulatory submission following successful late-stage trial of saroglitazar in primary biliary cholangitis.
Zydus Cadila, an Indian pharmaceutical company, has announced the success of its late-stage trial for saroglitazar in the treatment of primary biliary cholangitis (PBC). The company is now preparing to submit a New Drug Application (NDA) to the US FDA. Saroglitazar is a novel, oral, dual peroxisome proliferator-activated receptor (PPAR) agonist that has shown promising results in reducing alkaline phosphatase (ALP) levels, a key marker of PBC.
The phase 3 trial, which enrolled 130 patients, met its primary endpoint, demonstrating a statistically significant reduction in ALP levels from baseline to week 24. The results also showed that saroglitazar was well-tolerated, with a safety profile comparable to that of the placebo group. The trial’s success marks a significant milestone for Zydus, as it seeks to bring a new treatment option to patients with PBC, a chronic and progressive liver disease with limited treatment options.
PBC is a rare autoimmune disease that affects the bile ducts in the liver, leading to inflammation, scarring, and ultimately, liver failure. Current treatments for PBC, such as ursodeoxycholic acid (UDCA), are often ineffective in reducing ALP levels and slowing disease progression. Saroglitazar’s dual PPAR agonism mechanism is thought to provide a unique benefit in treating PBC, as it targets both PPAR-alpha and PPAR-gamma receptors, which play a crucial role in lipid metabolism and inflammation.
The success of saroglitazar in the phase 3 trial has significant implications for Zydus, as it prepares to enter the US market. The company plans to submit an NDA to the FDA, which, if approved, would make saroglitazar the first dual PPAR agonist available for the treatment of PBC in the US. Zydus’s submission is expected to be based on the results of the phase 3 trial, as well as additional data from ongoing and planned clinical studies.
The approval of saroglitazar in the US would not only expand treatment options for patients with PBC but also provide a new revenue stream for Zydus. The company has already received orphan drug designation for saroglitazar in the US, which provides incentives for the development of treatments for rare diseases, including tax credits, marketing exclusivity, and reduced regulatory fees. With its late-stage success and impending US application, Zydus is poised to make a significant impact in the treatment of PBC, a disease with limited treatment options and a high unmet medical need.
Apollo Hospitals Hyderabad celebrates 37 years of excellence, with Sangita Reddy and Tejesvi Rao Veerepalli looking back on a legacy built on innovative healthcare and unwavering trust.
Apollo Hospitals in Hyderabad recently celebrated its 37th anniversary, marking a significant milestone in its journey as a pioneering healthcare institution in India. The hospital was among the first private healthcare institutions in the country to provide world-class treatment, making it accessible to patients without the need to travel abroad. Over the decades, Apollo Hyderabad has introduced several innovations, including advanced imaging, robotic surgery, organ transplantation, and preventive health programs, while emphasizing the importance of combining compassion with technology.
The hospital’s anniversary celebration was attended by leaders, including Sangita Reddy, Joint Managing Director of Apollo Hospitals, and Tejesvi Rao Veerepalli, Vice President of Apollo Hospitals Hyderabad. Reddy reflected on the hospital’s story, noting that it is inseparable from the community it serves. She highlighted the hospital’s role in introducing new standards of care and inspiring confidence in millions of patients, contributing to Hyderabad’s growth as a center of science and medicine.
Veerepalli added that the hospital’s longevity is not measured only in years but in the lives touched. He recognized the dedication of long-serving doctors, nurses, and staff who have carried the institution’s culture of empathy and excellence forward. The anniversary celebrations included recognition of employees who have been with the hospital for a significant part of its journey, underscoring the idea that Apollo’s legacy lies as much in its people as in its technology.
As Apollo Hospitals Hyderabad moves into its 38th year, it remains committed to providing state-of-the-art infrastructure and care, combining tradition and innovation. The hospital’s story is a testament to the power of compassion and technology working together to make a positive impact on the community. The anniversary celebration was covered by Prittle Prattle News, a platform committed to disseminating powerful narratives that raise awareness and motivate change.
The hospital’s journey is a remarkable one, and its commitment to excellence and compassion has made it a trusted institution in the city. With its continued focus on innovation and customer care, Apollo Hospitals Hyderabad is poised to remain a leader in the healthcare industry for years to come. The hospital’s anniversary celebration was a fitting tribute to its dedication and inventiveness, and it serves as a reminder of the importance of combining technology and compassion in healthcare.
Piramal Pharma Solutions collaborates with George Medicines to create an innovative treatment for hypertension.
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has collaborated with George Medicines, a late-stage biopharma company, to develop WIDAPLIK, a new drug for the treatment of hypertension in adult patients. The US Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025. WIDAPLIK is a single pill combination of three medicines: telmisartan, amlodipine, and indapamide, developed in three doses. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.
The collaboration between George Medicines and Piramal Pharma Solutions began in December 2018, when the formulation was developed at Piramal’s Pharmaceutical Development site in Ahmedabad. The project was later transferred to Piramal’s drug product facility in Pithampur for validation and manufacturing. Piramal’s technical expertise and experience in advancing innovations played a significant role in achieving FDA approval for WIDAPLIK.
WIDAPLIK’s multi-mechanism approach and available doses are designed to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications. The drug is available in three strengths, including two doses that are lower than those currently available in single pill combinations.
The approval of WIDAPLIK marks a significant milestone in the treatment of hypertension, offering a new option for patients who require multiple medications to achieve blood pressure goals. Piramal Pharma Solutions’ robust CDMO capabilities and George Medicines’ commitment to developing innovative treatments have made this breakthrough possible. The collaboration demonstrates the importance of partnerships in advancing medical innovation and improving patient outcomes. With WIDAPLIK now approved, patients with hypertension can expect a more effective and convenient treatment option.
Nimulid forms a powerful alliance with the Patna Pirates for the upcoming Season 12 of the Pro Kabaddi League.
Mankind Pharma’s Nimulid Strong has partnered with the Patna Pirates as the Official Pain Relief Partner for Pro Kabaddi League Season 12. This partnership aligns the brand’s powerful pain relief formula with the intense physical demands of kabaddi, a sport known for sudden pulls, rapid twists, and heavy tackles that strain the neck and body. Nimulid Strong stands out in the topical pain relief market with a 2.32% diclofenac concentration, double the standard 1.16% found in most products.
The brand’s formula provides relief in just 2 minutes, making it ideal for players who need instant recovery. Nimulid Strong is available in gel and spray formats, targeting neck pain from intense kabaddi movements. The gel format provides deep-penetrating, long-lasting relief, while the spray format offers on-the-go convenience. In its first year, the brand has sold around 20 lakh gel units and 10 lakh spray units, demonstrating its remarkable market performance.
Mr. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, emphasized that the partnership celebrates India’s indigenous sport while supporting athletes and everyday warriors who push through pain. The company plans to expand the brand’s offerings with innovative formats like balms, roll-ons, and tablets, reinforcing its commitment to effective and accessible pain relief solutions.
The topical pain relief market in India is valued at over ₹5,000 crore, and Nimulid Strong’s unique formula and quick action have positioned it as a leader in this market. The partnership with the Patna Pirates is a strategic move to increase brand awareness and reach a wider audience. With its powerful pain relief formula and convenient formats, Nimulid Strong is well-positioned to become a go-to solution for individuals seeking quick and effective pain relief.
The collaboration between Mankind Pharma and the Patna Pirates is a win-win for both parties, as it promotes the brand’s products while supporting the team’s athletes and celebrating India’s indigenous sport. As the Pro Kabaddi League Season 12 progresses, Nimulid Strong’s partnership with the Patna Pirates is likely to increase brand visibility and drive sales, further solidifying its position in the topical pain relief market.
Two Pharmaceutical Firms Collaborate on State-of-the-Art Oral Solid Dose Manufacturing Facility in Sellersville
Two pharmaceutical companies have partnered to open a dedicated Oral Solid Dose (OSD) form suite in Sellersville, Pennsylvania. The partnership aims to provide a state-of-the-art facility for the development and manufacturing of oral solid dose pharmaceuticals. The new facility will offer a range of services, including formulation development, clinical trial manufacturing, and commercial production.
The OSD form suite is designed to meet the growing demand for oral solid dose pharmaceuticals, which are the most common form of medication. The facility will be equipped with cutting-edge technology and staffed by experienced professionals with expertise in pharmaceutical development and manufacturing. The partnership between the two companies brings together their collective knowledge and experience in the pharmaceutical industry, allowing them to offer a comprehensive range of services to clients.
The new facility will provide a range of benefits to clients, including faster turnaround times, increased flexibility, and improved quality control. The facility will also be designed to meet the highest standards of regulatory compliance, ensuring that all products manufactured there meet the strictest quality and safety standards.
The partnership between the two companies is a significant development in the pharmaceutical industry, as it brings together two experienced players with a deep understanding of the needs of clients. The new facility will be an important addition to the region’s pharmaceutical infrastructure, providing a range of services and expertise that will support the development and manufacturing of oral solid dose pharmaceuticals.
The opening of the dedicated OSD form suite in Sellersville is also expected to have a positive impact on the local economy, creating new job opportunities and stimulating economic growth. The facility will be an important hub for pharmaceutical development and manufacturing in the region, and its opening is a significant milestone in the partnership between the two companies.
Overall, the partnership between the two pharmaceutical companies to open a dedicated OSD form suite in Sellersville is an exciting development in the pharmaceutical industry. The new facility will provide a range of benefits to clients, including faster turnaround times, increased flexibility, and improved quality control. The partnership is also expected to have a positive impact on the local economy, creating new job opportunities and stimulating economic growth. With its state-of-the-art technology and experienced staff, the new facility is well-positioned to meet the growing demand for oral solid dose pharmaceuticals.
Zydus Lifesciences announces the passing of Samir Desai, President of its Biologics business unit.
Samir Desai, the President of the Biologics Business Unit at Zydus Lifesciences, has unfortunately passed away. Although the exact circumstances of his death are not specified, his passing is a significant loss to the organization and the pharmaceutical industry as a whole.
As the President of the Biologics Business Unit, Samir Desai played a crucial role in shaping the company’s strategy and direction in the biologics sector. Zydus Lifesciences is a leading pharmaceutical company that develops and manufactures a range of products, including biologics, which are medicinal products derived from living organisms. Under Desai’s leadership, the company has made significant strides in the biologics space, with a focus on developing innovative and affordable treatments for patients.
Desai’s experience and expertise in the pharmaceutical industry were extensive, and his loss will be deeply felt by his colleagues and peers. He was a respected leader and a driving force behind the company’s growth and success in the biologics sector. His passing will undoubtedly leave a void in the organization, and it will be challenging to replace his knowledge, expertise, and vision.
The news of Desai’s passing has likely sent shockwaves through the pharmaceutical industry, and his colleagues and friends will be mourning his loss. Zydus Lifesciences will need to regroup and re-evaluate its strategy in the biologics sector, but for now, the focus will be on paying tribute to Desai’s memory and celebrating his contributions to the company and the industry.
It’s worth noting that the article from which this information is derived uses cookies for analytics, advertising, and to improve the site. By continuing to use the site, users agree to the use of these cookies. For more information on the site’s cookie policy and settings, users can refer to the relevant sections.
In conclusion, Samir Desai’s passing is a significant loss to Zydus Lifesciences and the pharmaceutical industry. His leadership and expertise in the biologics sector will be deeply missed, and his contributions to the company’s growth and success will be remembered and celebrated. As the company moves forward, it will be essential to find a way to build on Desai’s legacy and continue to drive innovation and growth in the biologics sector.
Mankind Pharma Limited receives counsel from Luthra and Luthra, EPAM Law Offices for establishing its Russian subsidiary.
Mankind Pharma, an Indian pharmaceutical company, has successfully incorporated a subsidiary in Russia. This process was facilitated by Luthra and Luthra Law Offices India, which provided comprehensive legal advice and guidance. The law firm played a crucial role in structuring the subsidiary, ensuring compliance with Russian regulations, and navigating the complexities of international sanctions.
Luthra and Luthra Law Offices India coordinated with Russian counsel to ensure a seamless incorporation process. The firm’s expertise in cross-border transactions and regulatory matters was instrumental in overcoming the challenges posed by international sanctions. The team advised Mankind Pharma on the optimal structure for the subsidiary, taking into account the prevailing regulatory landscape.
The transaction was led by Pradnesh Warke, a partner at Luthra and Luthra Law Offices India, who brought his expertise in corporate law and cross-border transactions to the table. He was supported by a team of experienced lawyers, including Ravi Raj Shekhar, a senior associate, and associates Devashree Kulkarni and Tanay Jha. Together, they worked closely with Mankind Pharma to ensure that all documentation and regulatory requirements were met, facilitating a smooth incorporation process.
The incorporation of a subsidiary in Russia is a significant milestone for Mankind Pharma, marking its expansion into a new market. The company’s decision to establish a presence in Russia reflects its commitment to growing its global footprint and increasing its access to new markets. Luthra and Luthra Law Offices India’s role in this process demonstrates the firm’s capabilities in handling complex cross-border transactions and its ability to navigate challenging regulatory environments.
The success of this transaction is a testament to the strong partnership between Mankind Pharma and Luthra and Luthra Law Offices India. The law firm’s expertise and guidance were essential in ensuring that the incorporation process was completed efficiently and effectively, despite the complexities posed by international sanctions. As Mankind Pharma continues to expand its global presence, the company can rely on Luthra and Luthra Law Offices India to provide expert legal advice and support.
Piramal Pharma Releases Its FY2025 Sustainability Report, Outlining a Comprehensive Decarbonization Strategy
Piramal Pharma Limited (PPL) has released its FY2025 Sustainability Report, which highlights the company’s progress in integrating responsible practices across its operations worldwide. The report is themed “Innovating Responsibly, Growing Sustainably” and demonstrates measurable progress across four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
The company has made significant progress in various areas, including strengthening governance frameworks, accelerating decarbonization, advancing diversity and inclusion, and enhancing community impact through its CSR programs. Some key achievements include a 6% reduction in Scope 1 & 2 emissions, a 7.8% increase in renewable energy adoption, and a 90% recycling target for non-hazardous waste.
Piramal Pharma has also made significant strides in diversity and inclusion, with 30% women representation on the Board and 20% women in the global workforce. The company has also launched various initiatives to promote stakeholder centricity, including a women-led! skill development program and a partnership with the Life Sciences Sector Skill Development Council.
The company’s CSR initiatives have had a significant impact, with outreach to 112 aspirational districts and investments of ₹5.34 crore in initiatives such as school infrastructure upgrades, teacher training, and public health campaigns. Employee volunteering has also supported various community projects, including plantation drives, health awareness sessions, and community projects.
Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that sustainability is a deliberate choice for the company and that they remain committed to innovating responsibly and growing sustainably for patients, communities, and the planet. The company’s commitment to sustainable growth is aligned with GRI standards, SASB, and UNGC frameworks, and the report demonstrates Piramal Pharma’s commitment to responsible capital allocation, sustainable operations, and impactful stakeholder engagement.
Some of the key statistics from the report include:
* 50% independent directors on the Board
* 30% women representation on the Board
* 26.5% of critical suppliers assessed on sustainability
* 36 regulatory inspections successfully completed
* 165 customer audits conducted globally
* 6% reduction in Scope 1 & 2 emissions
* 7.8% increase in renewable energy adoption
* 90% recycling target for non-hazardous waste
* 2.10 lakh kiloliters of freshwater conserved through water stewardship initiatives
* 2,000+ saplings planted
* 30% green cover maintained across Indian sites
Overall, Piramal Pharma’s FY2025 Sustainability Report demonstrates the company’s commitment to sustainability and responsible growth, and highlights its progress in various areas, including governance, diversity and inclusion, and community impact.
Alkem Laboratories Sees Varied Results as Stakeholders Raise Concerns and Assessment Criteria Evolve
Alkem Laboratories, a midcap company in the Pharmaceuticals & Biotechnology sector, has undergone an evaluation adjustment due to changes in its underlying trends. The company’s financial performance is mixed, with a year-over-year return of -7.52% and a modest profit increase of 4.9%. Despite this, the company’s net sales growth has averaged 9.38% annually over the last five years, with operating profit growth at 9.03%. However, the recent quarter’s results have shown flat performance, raising concerns about long-term growth potential.
Promoter confidence in the company appears to be decreasing, with a 2.09% decrease in their stake, which now stands at 53.04%. This decline may indicate concerns about the company’s future trajectory. On the other hand, Alkem Laboratories maintains a high management efficiency, with a return on equity (ROE) of 17.69% and a low debt-to-equity ratio of 0 times. This suggests that the company is being managed effectively, despite the challenges it faces.
The recent evaluation adjustment reflects the complexities of Alkem Laboratories’ market position and performance indicators. The company’s mixed financial performance, combined with the decline in promoter confidence, raises questions about its long-term growth potential. However, the company’s high management efficiency and low debt-to-equity ratio are positive indicators that suggest it may be able to navigate these challenges.
Overall, Alkem Laboratories is facing a complex market position, with both positive and negative indicators. The company’s mixed financial performance and declining promoter confidence are concerns, but its high management efficiency and low debt-to-equity ratio are positives. As the company continues to navigate these challenges, it will be important to monitor its performance and adjust expectations accordingly. With the latest evaluation adjustment, it is essential for investors to reassess the company’s potential and make informed decisions about their investments.
Agenus to host August 27 webcast, featuring significant immuno-oncology updates, BOT/BAL data release, preview of BATTMAN, progress on Zydus partnership, and spotlight on MiNK.
Agenus Inc., a leading immuno-oncology company, has announced an update to its virtual Stakeholder Briefing, which will take place on August 27, 2025, at 4:00 p.m. ET. The webcast will provide a strategic and financial overview of the company, as well as updates on its partnerships, clinical trials, and product pipeline. The program will feature speakers including Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus, and Richard M. Goldberg, MD, Chief Development Officer of Agenus.
The webcast will cover several key topics, including the company’s Zydus partnership, patient needs in colorectal cancer studies, recent clinical updates on its botensilimab and balstilimab programs, and an overview of the Phase 3 BATTMAN study in metastatic colorectal cancer. Additionally, there will be a spotlight on MiNK Therapeutics, a company in which Agenus has a significant stake.
Agenus is a leader in the development of immunological agents for the treatment of cancer. The company’s pipeline includes a range of antibody therapeutics, adoptive cell therapies, and adjuvants. Its lead product, botensilimab, is a multifunctional antibody designed to boost anti-tumor immune responses. Botensilimab has shown clinical responses in several metastatic cancers, and is being evaluated in combination with Agenus’ investigational PD-1 antibody, balstilimab.
The company has also developed balstilimab, a novel monoclonal antibody designed to block PD-1. Balstilimab has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Agenus is headquartered in Lexington, MA, and has a global clinical operations footprint.
The webcast will conclude with a live Q&A session, and attendees can participate via a new virtual format. Pre-registration is not required, and the webcast link is available on the company’s website. Agenus cautions investors not to place undue reliance on forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from current expectations.
Biggest Global Pharma Firms of 2025: Ranking the Top 5
The pharmaceutical industry is a vital sector that produces life-saving medicines, vaccines, and treatments that improve global health. The top five largest pharmaceutical companies in the world, as of 2025, are Pfizer, Johnson & Johnson, AbbVie, Merck & Co., and Roche. These companies drive innovation in healthcare and supply essential drugs to the global market.
Pfizer remains the largest pharmaceutical company in 2025, with a revenue of $58.5 billion. Despite a decline in sales of pandemic-related products, Pfizer still grew by 7% in 2023, excluding COVID medicines. The company specializes in immunology, oncology, cardiology, neurology, and vaccines, and has made key moves such as acquiring Seagen Inc. to strengthen its oncology pipeline.
Johnson & Johnson ranks second, with a revenue of $54.8 billion. The company is known for its wide range of healthcare products and continues to perform strongly in pharmaceuticals. Its top medicines include Darzalex, Stelara, Tremfya, and Erleada, which treat multiple myeloma, autoimmune diseases, psoriasis, and prostate cancer.
AbbVie ranks third, with a revenue of $54.3 billion. However, its sales dipped due to the loss of exclusivity for Humira, once the world’s bestselling drug. The company is investing heavily in research and development and has made acquisitions such as ImmunoGen and Cerevel Therapeutics to strengthen its pipeline.
Merck & Co. ranks fourth, with a revenue of $53.6 billion. The company has a history of over 130 years and focuses on pharmaceuticals, vaccines, and animal health. Its top product, Keytruda, contributed nearly half of its pharma revenues, reaching $25 billion. The company is preparing for Keytruda’s patent expiry in 2028 and has made acquisitions such as Prometheus Biosciences and Harpoon Therapeutics to expand into immunology.
Roche rounds out the top five, with a revenue of $49.9 billion. The company has a history of over 128 years and focuses on oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Despite lower sales in COVID-related products, new drugs like Vabysmo grew rapidly, up 85% in 2023. The company is expanding into cardiometabolic diseases and inflammatory conditions through partnerships and acquisitions.
These top five pharmaceutical companies are driving innovation in healthcare and shaping the future of global medicine. They are investing heavily in research and development, making strategic acquisitions, and expanding their product portfolios to meet the evolving needs of the global market. As the pharmaceutical industry continues to evolve, these companies are well-positioned to remain leaders in the sector.
Garmin and Apollo HealthAxis strengthen their strategic partnership.
Garmin and Apollo HealthAxis have announced a deepening of their strategic collaboration. The partnership aims to reimagine Indian healthcare by integrating Garmin’s wearable technology with Apollo HealthAxis’s healthcare services.
The collaboration will focus on preventive healthcare, leveraging Garmin’s wearable devices to track users’ vital signs, physical activity, and other health metrics. Apollo HealthAxis will utilize this data to provide personalized health and wellness services, including consultations, diagnostics, and treatment plans.
By combining their expertise, Garmin and Apollo HealthAxis seek to promote proactive healthcare management, enabling individuals to take control of their health and wellbeing. The partnership will also facilitate the development of customized wellness programs, tailored to meet the specific needs of users.
Garmin’s wearable devices, such as smartwatches and fitness trackers, will play a crucial role in the collaboration. These devices will collect data on users’ health and fitness metrics, including heart rate, sleep patterns, and physical activity levels. This data will be shared with Apollo HealthAxis, allowing their healthcare professionals to gain a more comprehensive understanding of users’ health needs.
Apollo HealthAxis will then use this data to provide personalized health recommendations, consultations, and interventions. The organization’s healthcare experts will work closely with users to develop customized wellness plans, addressing specific health concerns and goals.
The deepened collaboration between Garmin and Apollo HealthAxis highlights the growing importance of preventive healthcare in India. By leveraging wearable technology and healthcare services, the partnership aims to empower individuals to take a more proactive approach to their health and wellbeing.
The integration of Garmin’s wearable devices with Apollo HealthAxis’s healthcare services has the potential to transform the Indian healthcare landscape. By providing personalized, data-driven healthcare solutions, the partnership seeks to improve health outcomes, enhance user experience, and reduce healthcare costs.
Overall, the strategic collaboration between Garmin and Apollo HealthAxis represents a significant step forward in the pursuit of innovative, patient-centric healthcare solutions in India. As the partnership continues to evolve, it is likely to have a profound impact on the country’s healthcare ecosystem, enabling individuals to lead healthier, more fulfilling lives.
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce pharmaceutical expenditure, and growing awareness of cost-effective alternatives. The market is also driven by local manufacturing and government support for generics.
The demand for generic medications in Saudi Arabia is increasing rapidly, driven by the government’s attempts to reduce reliance on imported branded medicines and lower healthcare spending. The Saudi Food and Drug Authority (SFDA) has simplified the process of generic approvals, encouraging local and foreign manufacturers to increase their generic offerings.
Key growth drivers in the Saudi Arabia Generic Drugs Market include government support and cost containment initiatives, increasing incidence of chronic diseases, and growing local production capability. The government has focused on making healthcare more affordable through greater generic drug promotion, and initiatives such as the “Procedure to deal with patents when registering generic products in SFDA” have been introduced to facilitate the growth of the generic drug market.
However, the market also faces challenges, including public perception and brand loyalty, as well as regulatory and quality control complexity. Despite these challenges, the market is expected to continue growing, driven by the increasing demand for cost-effective generic drugs.
The report provides an in-depth analysis of the Saudi Arabia Generic Drugs Market, including market trends, forecast, and key players analysis. The market is segmented by type, route of administration, therapeutic area, distribution channel, and region. Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group AG, and Sun Pharmaceutical Industries Ltd.
The report also highlights the growing trend of online generic drugs in Saudi Arabia, with digital platforms and e-pharmacies facilitating easier price comparisons and prescription-based generics ordering for consumers. The online generic drug segment is expected to receive robust traction, particularly in urban regions such as Riyadh and Jeddah.
In terms of therapeutic areas, the report highlights the growing demand for generic drugs in areas such as respiratory, oncology, and infectious diseases. The report also provides an analysis of the regulatory framework of generic drugs in Saudi Arabia, including the role of the SFDA and the challenges faced by manufacturers in complying with regulatory requirements.
Overall, the Saudi Arabia Generic Drugs Market is expected to continue growing, driven by government support, increasing demand for cost-effective generic drugs, and growing local production capability. The report provides a comprehensive analysis of the market, including key trends, challenges, and opportunities, and is a valuable resource for companies looking to enter or expand their presence in the Saudi Arabian generic drugs market.
India is on the cusp of becoming the globe’s premier healthcare hub.
Dr. Prathap C Reddy, Founder-Chairman of Apollo Hospitals and Chancellor of Apollo University, has expressed his confidence that India is on the verge of becoming the world’s healthcare capital. He made this statement while addressing students and faculty at Apollo Knowledge City in Chittoor. Dr. Reddy highlighted India’s growing presence in the global medical field, citing the fact that nearly 10% of doctors in the US and up to 30% in the UK are of Indian origin. This, he believes, is a testament to the talent and dedication of Indian medical professionals.
Dr. Reddy emphasized the potential of India’s youth to make the country a global healthcare hub, provided they receive proper training and guidance. He recalled the pioneering role of Apollo Hospitals in cardiology, including complex surgeries and heart transplants, which has eliminated the need for patients to travel abroad for treatment. He also mentioned Apollo’s efforts in introducing advanced technologies, such as proton therapy for cancer treatment, in cities like Delhi and Hyderabad.
Dr. Reddy stressed that healthcare encompasses not only medicine but also technology, preventive care, and emergency services. He noted that Apollo University is integrating engineering education to drive medical innovations, underscoring the importance of a multidisciplinary approach to healthcare. The event was attended by various dignitaries, including Apollo University Vice Chancellor Dr. H Vinod Bhat, Registrar Prof M Potharaju, and a large gathering of students.
Dr. Reddy’s vision for India as a global healthcare capital is built on the country’s existing strengths in medical talent and innovation. With the right support and guidance, he believes that India’s youth can play a crucial role in making this vision a reality. The event served as a motivational platform for students and faculty, encouraging them to strive for excellence in the field of healthcare and contribute to India’s emergence as a global healthcare hub. Overall, Dr. Reddy’s speech highlighted the vast potential of India’s healthcare sector and the importance of investing in the country’s youth to achieve this goal.
Sikkim High Court Overturns GST Ruling, Restores Rs. 59 Lakh Budgetary Support to Zydus Wellness
The High Court of Sikkim has recently overturned a decision by the GST authorities to deny Zydus Wellness budgetary support of ₹59.44 lakh. The court ruled that the rejection was “untenable in law” and went against established judicial precedent. The GST authorities had rejected Zydus Wellness’ claim for budgetary support under the Scheme of Budgetary Support to Eligible Industrial Units in the North Eastern Region and Himalayan States, 2017. The Assistant Commissioner of Central Goods and Services Tax had concluded that the eligible support was “in the negative” and therefore, the company was not entitled to any benefit.
Zydus Wellness challenged this decision under Article 226 of the Constitution, arguing that the issue had already been settled by a Division Bench of the same High Court in a previous case, Glenmark Pharmaceuticals Limited v. Union of India (2024). In that case, the court had relied on a decision by the Jammu & Kashmir and Ladakh High Court, which clarified that budgetary support claims must be calculated on the basis of monthly tax payments through the cash ledger, rather than on a quarterly basis as interpreted by the authorities.
The High Court of Sikkim set aside the order dated 27 June 2022 passed by the Assistant Commissioner of CGST and directed that Zydus Wellness’ claim be reconsidered in line with the principles laid down in the Glenmark Pharmaceuticals and Coromandel International rulings. The court’s decision is a significant victory for Zydus Wellness, which will now be eligible to receive the budgetary support of ₹59.44 lakh.
The case, Zydus Wellness-Sikkim vs The Assistant Commissioner, was heard by Justice Meenakshi Madan Rai, who delivered the judgment on 11 August 2025. The counsel for the appellant, Mr. Mayank Jain, and the counsel for the respondent, Ms. Sangita Pradhan, presented their arguments in the case. The court’s decision has been cited as 2025 TAXSCAN (HC) 1725, and the case number is WP(C) No.10 of 2024. The ruling provides clarity on the calculation of budgetary support claims and will have implications for other companies operating in the North Eastern Region and Himalayan States.
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and Johnson, and Sanofi separating their consumer healthcare divisions. The rationale behind this strategy is to create a separate entity that can operate with a more agile and fast-moving consumer goods (FMCG) mindset, allowing for more focused marketing and advertising efforts.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company’s objective was to create a separate division for its over-the-counter (OTC) brands, which require a different environment, culture, and talent compared to prescription brands. The company had previously run its OTC business like its prescription business, but found that it was not effective. Juneja explains that some prescription brands can be transitioned to the consumer healthcare business within the regulatory framework, but everything should be different, including management, to stay focused and agile.
Subhakanta Bal, Managing Director and Head of Healthcare and Consumer at Rothschild & Co, notes that there are commonalities between consumer healthcare and the core prescription-driven business, but also differences. For example, consumer healthcare requires a more FMCG-like mindset, with a focus on marketing and advertising to drive sales. Bal observes that pharma companies often bring in FMCG veterans to run their consumer healthcare divisions, and that a separate entity can be more “fit for purpose”.
The pursuit of growth is the key reason behind the consumer healthcare demerging trend, according to Vishal Manchanda, Senior Vice-President at Systematix Group. Pharma companies are developing a second platform for growth, given the challenges in the domestic branded business and global uncertainties. However, it’s not an easy task, with intense competition from store-owned brands and pressure on prices.
The demerging of consumer healthcare businesses is expected to lead to better value realization, potentially through listing, as FMCG businesses in India trade at a higher value than domestic formulation businesses. Internationally, big pharma companies have separated or exited consumer healthcare to focus on innovation, but in India, the trend is driven by the need for right managerial talent, marketing, and advertising to ensure success. As the Indian pharmaceutical industry continues to evolve, the demerging of consumer healthcare businesses is likely to be a key strategy for growth and expansion.
Does Enanta’s Lawsuit and PADCEV Trial’s Positive Outcomes Alter Pfizer’s (PFE) Investment Storyline?
Pfizer, a leading pharmaceutical company, is facing a crucial period as it navigates through patent litigation and promising cancer trial results. Enanta Pharmaceuticals has initiated a lawsuit against Pfizer in the European Unified Patent Court, alleging infringement of a newly granted COVID-19 antiviral patent. This lawsuit adds to the existing risks faced by Pfizer, including patent expirations and tightening regulatory policies.
However, Pfizer has announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer patients not eligible for cisplatin-based therapy. This combination of promising cancer trial results and fresh EU patent litigation marks a pivotal period as Pfizer’s innovation meets potential hurdles in its COVID-19 portfolio.
The successful PADCEV and KEYTRUDA trial could update Pfizer’s outlook, as it underpins the company’s opportunity to offset potential revenue loss from patent expirations with strong new clinical trial outcomes. These results not only reinforce confidence in Pfizer’s oncology pipeline but also support a key catalyst, successful new product launches that could help bridge the gap created by expiring exclusivity on high-revenue drugs.
Pfizer’s outlook anticipates $59.7 billion in revenue and $13.2 billion in earnings by 2028, reflecting a 2.2% annual revenue decline and a $2.5 billion increase in earnings from the current $10.7 billion. Some analysts see regulatory hurdles and expiring patents as constraining, while others expect revenues to fall to $56.1 billion by 2028.
Investors should stay alert as legal challenges could escalate, and new patent litigation may impact forecasts. The article emphasizes the importance of considering alternative viewpoints and exploring other perspectives on Pfizer’s future. The company’s forecasts yield a $28.77 fair value, a 11% upside to its current price. Despite the challenges, Pfizer’s innovation and promising cancer trial results could energize its growth story, making it an attractive investment opportunity.
Overall, Pfizer’s future is uncertain, with both opportunities and risks on the horizon. Investors should carefully consider the company’s outlook, taking into account the potential impact of patent litigation, regulatory hurdles, and promising cancer trial results. By analyzing the company’s forecasts and considering alternative viewpoints, investors can make informed decisions about their investment in Pfizer.
Apollo Hospital reaches milestone of 600 successful pediatric liver transplants, commemorated with book release, as reported by The Week.
Two doctors from Apollo Hospital in New Delhi, Dr. Smita Malhotra and Dr. Anupam Sibal, have authored a book titled “Transplanting Hope” to commemorate the hospital’s 600th pediatric liver transplant. The book is an anthology of 25 stories that showcase the grit, courage, and perseverance of children facing life-threatening liver diseases. Each story captures the emotional battles, medical challenges, and moments of hope that define the journey of these young patients.
The book has a foreword by Indian cricket coach Gautam Gambhir, who praises the authenticity and emotional depth of the stories. The authors aim to go beyond statistics and clinical facts to portray the human spirit that transforms despair into determination. The book highlights the strength and resilience of the children and their families, who have fought against all odds to overcome their medical challenges.
According to Dr. Anupam Sibal, the book is a testament to the power of medicine, humanity, courage, and hope. He emphasizes that medicine is not just about science, but also about the human spirit and the sacrifices made by families. Dr. Smita Malhotra adds that while the book celebrates the triumphs, it also acknowledges the heartbreaks and setbacks that remind them of the need to keep advancing and fighting for better outcomes.
The hospital’s Managing Director, P Shivakumar, notes that the milestone of 600 pediatric liver transplants is a matter of pride not just for Apollo Hospitals, but for Indian healthcare as a whole. The hospital’s mission has been to give children a chance at life and families a chance at hope since its first successful pediatric liver transplant in 1998.
The book has been praised by Dr. Neerav Goel, Chief Liver Transplant Surgeon, who says that it beautifully captures the essence of their daily work, celebrating medical breakthroughs while honoring the emotional journeys behind them. Gautam Gambhir’s foreword commends the book as a collection of 25 sagas of hope, courage, and human perseverance against all odds, noting that each story is real and authentic, with no scripted or grey areas. Overall, “Transplanting Hope” is a powerful and inspiring book that showcases the human spirit and the power of medicine to transform lives.
Piramal Pharma has inaugurated a US-based facility for the production of Oral Solid Dosage (OSD) formulations, as reported by ICICI Direct.
Piramal Pharma has announced the opening of its new facility in the USA for the production of Oral Solid Dosage (OSD) forms. This move is expected to enhance the company’s capabilities in the global pharmaceutical market.
The new facility, located in the United States, will enable Piramal Pharma to leverage its expertise in OSD production to cater to the growing demands of the global pharmaceutical industry. The company has invested significantly in this facility, which is equipped with state-of-the-art technology and equipment to ensure high-quality production.
Piramal Pharma’s decision to open a facility in the USA is a strategic one, as it will allow the company to strengthen its presence in the North American market. The USA is one of the largest pharmaceutical markets in the world, and having a local production facility will enable Piramal Pharma to better serve its customers in the region.
The facility will produce a range of OSD products, including tablets, capsules, and other solid oral dosages. Piramal Pharma has a strong track record of producing high-quality pharmaceutical products, and the new facility will adhere to the same stringent quality standards. The company’s expertise in OSD production, combined with its commitment to quality, will enable it to deliver products that meet the exacting standards of the global pharmaceutical industry.
The opening of the new facility is also expected to create new job opportunities in the region. Piramal Pharma is committed to contributing to the local economy and has plans to hire skilled personnel to work at the facility. This will not only benefit the local community but also enhance the company’s capabilities in the region.
Piramal Pharma’s expansion into the USA is a significant milestone for the company, and it underscores its commitment to becoming a leading global pharmaceutical player. The company’s strategic decision to open a facility in the USA is expected to drive growth and expansion, and it will enable Piramal Pharma to better serve its customers in the North American market.
Overall, the opening of Piramal Pharma’s new facility in the USA is a positive development for the company and the global pharmaceutical industry. It highlights the company’s commitment to quality, innovation, and customer satisfaction, and it is expected to drive growth and expansion in the years to come. With its strong track record of producing high-quality pharmaceutical products, Piramal Pharma is well-positioned to become a leading player in the global pharmaceutical market.
PFE transformation as a market catalyst fuels Institutional Tactics with a Liquidity Pulse, revolutionizing asset management strategies.
The key findings for Pfizer Inc. (NYSE: PFE) indicate a strong sentiment in the near and mid-term, but a weak long-term outlook. The analysis reveals no clear price positioning signal, but the upside opportunity looks excellent as long as the converted support holds. The current price is $25.82, with signals identified at $21.21, $23.10, $24.87, and $25.82.
The institutional trading strategies are generated by AI models, which provide three distinct trading strategies tailored to different risk profiles and holding periods. These strategies incorporate sophisticated risk management parameters to optimize position sizing and minimize drawdown risk.
The multi-timeframe signal analysis provides a breakdown of the signal strength and support and resistance signals for different time horizons. In the near-term (1-5 days), the signal strength is strong, with a support signal at $25.63 and a resistance signal at $25.87. In the mid-term (5-20 days), the signal strength is also strong, with a support signal at $25.56 and a resistance signal at $25.92. However, in the long-term (20+ days), the signal strength is weak, with a support signal at $23.10 and a resistance signal at $24.87.
The AI-generated signals for PFE are represented by different colors, with blue indicating the current price, red indicating resistance, and green indicating support. The analysis suggests that positive sentiment is prevailing, and investors can use the current signals for positioning and risk parameters. Overall, the analysis provides a comprehensive view of the market sentiment and trends for Pfizer Inc., helping investors make informed decisions about their trading strategies.
It is essential to note that the long-term outlook is weak, which may indicate a potential shift in the market sentiment. However, the near and mid-term strong sentiment could provide excellent upside opportunities if the converted support holds. Investors should carefully consider the risk management parameters and position sizing to minimize drawdown risk and optimize their trading strategies.
Natco Pharma files lawsuit against Novo Nordisk in Delhi courts regarding intellectual property dispute over Semaglutide.
Natco Pharma, an Indian pharmaceutical company, has filed a lawsuit against Novo Nordisk, a Danish multinational pharmaceutical company, in a Delhi court over intellectual property rights related to semaglutide. Semaglutide is a medication used to treat type 2 diabetes and has shown significant potential in the treatment of obesity.
Natco Pharma is seeking to launch its own version of semaglutide in the Indian market, which is expected to be a significant opportunity for the company. The Indian firm hopes to be a major player in the market when it forms next year, as the demand for semaglutide is expected to increase rapidly.
Novo Nordisk currently holds the patent for semaglutide and has been marketing it under the brand name Ozempic. However, Natco Pharma claims that its own version of the medication does not infringe on Novo Nordisk’s patent, and the company is seeking a declaration from the court to this effect.
The lawsuit is seen as a significant development in the Indian pharmaceutical industry, where generic versions of popular medications are in high demand. Natco Pharma’s move is expected to be closely watched by other Indian pharmaceutical companies, which may also be looking to launch their own versions of semaglutide.
The outcome of the lawsuit is uncertain, and it may take several months or even years to resolve. However, if Natco Pharma is successful in its claim, it could pave the way for other Indian companies to launch their own versions of semaglutide, which could lead to increased competition and lower prices for the medication in the Indian market.
Novo Nordisk has not commented on the lawsuit, but the company has been actively defending its patent for semaglutide in other countries. The Danish company has been facing challenges from other generic manufacturers, and the lawsuit in India is just the latest development in this ongoing saga.
The Indian market for semaglutide is expected to be significant, with the country having a large population of people with type 2 diabetes and obesity. The demand for effective treatments for these conditions is high, and companies like Natco Pharma are looking to capitalize on this demand by launching their own versions of semaglutide.
Overall, the lawsuit between Natco Pharma and Novo Nordisk is a significant development in the Indian pharmaceutical industry, and the outcome will be closely watched by other companies and stakeholders. The case has the potential to shape the future of the semaglutide market in India and could have implications for the broader pharmaceutical industry.
Work Halts at David Werner’s Conversion of Metro Loft’s Pfizer Headquarters
A suspected fire at the former Pfizer headquarters in Manhattan, currently under construction for a residential conversion, prompted a response from authorities. The incident occurred at 235 East 42nd Street, where Nathan Berman’s Metro Loft and David Werner are working on the largest office-to-residential conversion in New York City. The construction site was temporarily halted, with hundreds of workers waiting on the sidewalk, while the fire department investigated the situation.
According to eyewitness accounts and videos, smoke was seen coming from the construction site, leading to the New York Fire Department being called. However, no actual fire was found, and no damage was reported. Work resumed after a brief investigation, with the construction crew member stating that work was halted for about 20 minutes.
The conversion project aims to transform the former Pfizer headquarters into approximately 1,500 rental units, including a mix of luxury rentals and affordable housing through the 467a tax abatement program. The developers have secured significant financing for the project, including a record $700 million construction loan from Madison Realty Capital in May. Additionally, Northwind Group provided a $75 million loan for the property at 219 East 42nd Street and a further $135 million in January.
The combined property will feature over 100,000 square feet of amenities and 30,000 square feet of retail space. Construction is expected to be completed by the last quarter of 2027. Nathan Berman’s Metro Loft and David Werner’s joint venture have been working on the project, with Werner owning the leasehold of the larger building and having purchased the smaller building in partnership with Alexandria Real Estate Equities before buying out the real estate investment trust.
The project has been making progress, with the developers navigating several rounds of financing to bring the massive undertaking to fruition. The conversion of the former Pfizer headquarters is a significant undertaking, and its completion is anticipated to bring a new wave of residential units to the Midtown area. With the project’s expected completion date and the significant financing secured, the developers are on track to deliver a unique and extensive residential offering in Manhattan.
Apollo remains poised for consistent growth in earnings.
According to a report by Reliance Securities, Apollo Hospitals is poised for significant growth and expansion in the future. The hospital chain is expected to benefit from several key factors, including the expansion of its bed capacity, an increase in international patient inflows, and a focus on specialty-led growth. These strategic initiatives are expected to drive revenue and profitability for the company.
In addition to these growth drivers, Apollo Hospitals’ subsidiary, HealthCo, is also on track to achieve cost efficiencies and break even digitally. This is expected to further enhance the company’s profitability and competitiveness in the market. The report by Reliance Securities highlights the potential for Apollo Hospitals to unlock value through various means, including the merger with Keimed and the listing of its pharmacy business.
The report notes that Apollo Hospitals has resilient margins and is experiencing improving profitability, which positions the company well for steady earnings expansion. The strategic levers mentioned earlier, including the Keimed merger and pharmacy business listing, add further upside potential to the company’s growth prospects.
Overall, the report suggests that Apollo Hospitals is well-placed to continue its growth trajectory, driven by a combination of strategic initiatives and value-unlocking opportunities. The company’s focus on expanding its bed capacity, increasing international patient inflows, and driving specialty-led growth is expected to drive revenue and profitability, while the cost efficiencies and digital breakeven achieved by HealthCo will further enhance the company’s competitiveness.
With its strong fundamentals and growth prospects, Apollo Hospitals is expected to continue to deliver steady earnings expansion, making it an attractive investment opportunity. The report by Reliance Securities provides a positive outlook for the company, highlighting its potential for long-term growth and value creation. As the healthcare industry continues to evolve, Apollo Hospitals is poised to remain a leading player, driven by its strategic initiatives and commitment to delivering high-quality patient care.
Makers of generic drugs agree to pay 71 million dollars to settle allegations of price-fixing.
Glenmark Pharmaceuticals Inc. USA and Pfizer Inc., along with its generic-drug unit Greenstone LLC, have reached a settlement agreement to resolve price-fixing claims brought by direct purchasers of generic drugs. According to the terms of the agreement, Glenmark Pharmaceuticals will pay approximately $38 million, while Pfizer and Greenstone will pay around $33 million.
The settlement is the latest development in a long-running dispute over allegations of price-fixing in the generic drug market. The direct purchasers, who include companies that buy generic drugs directly from manufacturers, had accused several major pharmaceutical companies, including Glenmark and Pfizer, of colluding to artificially inflate prices.
By settling the claims, Glenmark and Pfizer are able to avoid the uncertainty and potential risks associated with litigating the matter in court. The settlement agreement is expected to bring closure to the dispute and provide compensation to the direct purchasers who were affected by the alleged price-fixing scheme.
The case highlights the ongoing scrutiny of the pharmaceutical industry, particularly with regards to the pricing of generic drugs. Generics are copycat versions of brand-name drugs that are designed to be more affordable, but some manufacturers have been accused of exploiting their market power to drive up prices.
Law360, a leading source of legal news and analysis, has been closely following the case and providing updates on the latest developments. With its comprehensive coverage of the pharmaceutical industry and antitrust law, Law360 is an essential resource for professionals who need to stay up-to-date on the latest trends and developments.
In addition to its daily news coverage, Law360 offers a range of features, including expert analysis, mobile apps, and advanced search functionality. Subscribers can access a vast archive of articles, as well as real-time alerts and judge information. With a free 7-day trial, readers can experience the benefits of Law360’s comprehensive coverage and expert analysis for themselves.
Kiran Mazumdar-Shaw of Biocon calls for sweeping changes to accelerate the transition of innovations from laboratories to the market.
On India’s 79th Independence Day, Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics, welcomed Prime Minister Narendra Modi’s emphasis on self-reliance, innovation, and reform. Shaw noted that Modi’s vision extends beyond self-reliance to making India “globally competitive” through innovation that delivers affordability. She also highlighted the importance of GST reforms to reduce the cost of essentials, which would be a significant step towards making products more affordable.
Shaw agreed with Modi’s message to the pharmaceutical industry, emphasizing the need to invest in research and cutting-edge technologies. She stressed that the sector requires regulatory reforms to enable innovation, citing the lengthy and costly journey from “lab to market” as a key bottleneck. Shaw explained that the current regulatory framework makes investments in innovative molecules “high risk” and deters funding. She emphasized the importance of developing homegrown solutions rather than relying on products developed overseas.
Shaw cited China as an example of how regulatory ecosystems can drive domestic innovation. She urged regulators to play a crucial role in supporting research and innovation in India, enabling the country to take its innovations to the world. On the potential impact of Modi’s announcements on global ratings agencies, Shaw took a broader view, noting that the Independence Day speech is not a budget speech. However, she expressed hope that the “very strong intent for regulatory reforms” could pave the way for broader reform momentum.
Shaw’s comments highlight the need for urgent regulatory changes in the pharma sector to realize the vision of self-reliance and innovation. The industry requires bold regulatory reforms to shorten the journey from lab to market, enabling investments in innovative molecules and driving domestic innovation. With the right regulatory framework, India can develop homegrown solutions, reduce its reliance on overseas products, and become a globally competitive player in the pharmaceutical industry. Overall, Shaw’s remarks emphasize the importance of regulatory reforms in supporting India’s vision of self-reliance and innovation, and the need for urgent action to drive growth and development in the pharma sector.
Apollo Hospitals in India plans to double its investments in artificial intelligence after surpassing profit expectations.
Apollo Hospitals, one of India’s largest private healthcare providers, has announced plans to double its investments in artificial intelligence (AI) over the next two years. The move is aimed at improving patient outcomes, enhancing operational efficiency, and expanding its reach in the country’s growing healthcare market. The company’s decision to boost AI investments comes on the back of strong financial performance, with its quarterly profit beating analyst estimates.
Apollo Hospitals reported a net profit of ₹134.26 crore ($18.2 million) for the quarter ended December, exceeding analyst expectations of ₹128.4 crore ($17.4 million). The company’s revenue from operations rose 18% year-on-year to ₹2,441.6 crore ($331.5 million), driven by growth in its hospital and pharmacy segments. The strong financial performance has given the company the confidence to accelerate its digital transformation journey, with AI playing a key role in its strategy.
Apollo Hospitals has already implemented AI-powered solutions in various aspects of its operations, including diagnosis, patient engagement, and operational efficiency. The company has partnered with various technology startups and companies, including Microsoft and IBM, to develop and implement AI-based solutions. With its enhanced AI investments, Apollo Hospitals aims to further leverage machine learning, natural language processing, and computer vision to improve patient care and experience.
The company plans to deploy AI-powered chatbots to enhance patient engagement and provide personalized healthcare services. Additionally, Apollo Hospitals will use AI to analyze medical data and develop predictive models to improve diagnosis and treatment outcomes. The company also aims to use AI to optimize operational efficiency, streamline clinical workflows, and reduce costs.
Apollo Hospitals’ decision to double its AI investments reflects the growing trend of adopting digital technologies in India’s healthcare sector. The company’s focus on AI is expected to not only improve patient outcomes but also provide a competitive edge in the market. With the Indian government’s push for digital healthcare and the increasing demand for quality healthcare services, Apollo Hospitals is well-positioned to leverage AI and other digital technologies to drive growth and expansion. Overall, the company’s strong financial performance and plans to boost AI investments indicate a promising future for Apollo Hospitals and the Indian healthcare sector as a whole.
CDSCO Panel Approves Sun Pharma’s Phase IV Clinical Trial for Dual Release Pantoprazole in Treating Gastroesophageal Reflux Disease (GERD)
Sun Pharma, a leading pharmaceutical company, has announced that its Phase IV study on dual release pantoprazole for the treatment of Gastroesophageal Reflux Disease (GERD) has received acceptance from the Central Drugs Standard Control Organization (CDSCO) panel. This milestone marks a significant step forward in the development of a new treatment option for patients suffering from GERD.
GERD is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Pantoprazole is a proton pump inhibitor (PPI) that works by reducing the amount of acid produced in the stomach. The dual release formulation of pantoprazole developed by Sun Pharma is designed to provide both immediate and sustained release of the medication, offering enhanced efficacy and convenience for patients.
The Phase IV study, which was conducted in accordance with CDSCO guidelines, aimed to evaluate the safety and efficacy of dual release pantoprazole in patients with GERD. The study’s findings were presented to the CDSCO panel, which has now accepted the results. This acceptance is a crucial step towards obtaining regulatory approval for the new formulation.
The CDSCO panel’s acceptance of the study’s results is a testament to the rigor and quality of Sun Pharma’s research and development efforts. The company’s commitment to improving patient outcomes and addressing unmet medical needs is evident in its pursuit of innovative treatment options like dual release pantoprazole.
With this development, Sun Pharma is poised to bring a new treatment option to patients with GERD, offering them a potentially more effective and convenient way to manage their symptoms. The company’s expertise in formulation development and its strong regulatory capabilities have enabled it to navigate the complex regulatory landscape and achieve this milestone.
As the pharmaceutical industry continues to evolve, companies like Sun Pharma are at the forefront of innovation, driving progress in the development of new treatments and therapies. The acceptance of the Phase IV study on dual release pantoprazole by the CDSCO panel is a significant achievement, demonstrating Sun Pharma’s capabilities and commitment to delivering high-quality, effective treatments to patients.
Volini by Sun Pharma Introduces ‘Uparna’, a Groundbreaking Initiative for Devotees Traveling to Pandharpur
Sun Pharmaceutical Industries Limited, India’s leading pharmaceutical company, has launched a unique initiative through its pain relief brand, Volini. During the annual Pandharpur Wari pilgrimage in Maharashtra, one of the oldest and most significant spiritual journeys in the state, Volini introduced the “Volini Uparna”. This innovative product is a modern twist on the traditional Uparna, a multipurpose cloth worn by pilgrims over their shoulders, symbolizing comfort, resilience, and faith.
The Uparna has been redesigned to include a specially designed sleeve that holds Volini Gel, providing instant pain relief for sore muscles and joints. This allows pilgrims to access pain relief on the go, making their 21-day, 250-kilometer journey more comfortable. The initiative was launched at Pirachi Kuroli, a key rest point along the pilgrimage route, where local residents and the Volini team distributed the Uparnas to pilgrims.
This effort is an extension of Volini’s long-standing tradition of supporting the Warkaris, the pilgrims who undertake the Pandharpur Wari journey, through on-ground pain relief camps. The Volini Uparna reflects the brand’s promise of “No Time for Pain” and positions Volini as a meaningful cultural companion, rather than just a pain relief solution. By incorporating its core product into a culturally significant item, Sun Pharma has demonstrated a deep understanding of consumer needs and cultural heritage.
The Volini Uparna is an innovative example of how a brand can blend tradition and utility to create a meaningful and functional product. It showcases Volini’s commitment to providing pain relief solutions that are both effective and culturally relevant. With over three million pilgrims participating in the Pandharpur Wari each year, the Volini Uparna has the potential to make a significant impact on the lives of those undertaking this spiritual journey. By reimagining a traditional item with a modern twist, Volini has created a unique and memorable brand experience that is likely to resonate with consumers and reinforce its position as a leader in the Indian pharmaceutical industry.
Fortis acquires Shrimann hospital in a massive Rs 462 crore deal
Fortis Healthcare has expanded its presence in Punjab by acquiring the 228-bed Shrimann Superspecialty Hospital for a consideration of Rs 462 crore. This marks the fifth hospital of Fortis in Punjab, with existing hospitals in Ludhiana, Mohali, and Amritsar. The acquired hospital is located on the Pathankot road and is built on a 3-acre land parcel. Fortis plans to expand the hospital’s capacity by adding 225 more beds, utilizing an adjacent 2.4-acre land chunk, taking the total bed count to over 450.
The hospital currently has a staff of 65 doctors and 1,000 support staff, which Fortis aims to retain while adding more specialists to the existing team. The medical charges for treatment will remain the same, ensuring continuity for patients. The hospital already has 25 specialty departments, including cardiac sciences, renal sciences, general and laparoscopic surgery, oncology, orthopaedics, neurosciences, and gastroenterology.
The hospital is equipped with advanced technologies such as PET Scan, fibroscan, and 28 dialysis beds, along with four advanced Operation Theatres and a Cath Lab. Fortis plans to add more advanced technologies to enhance patient care. The hospital is already empaneled with prominent government agencies, including the Ex-Servicemen Contributory Health Scheme (ECHS), Central Government Health Scheme (CGHS), Northern Railways, and the Central Armed Police Forces.
The promoters of Shrimann Hospital, Dr. V P Sharma, Dr. Harmeet Paul Singh, Dr. Rajeev Bhatia, and Dr. Ajay Marwaha, have welcomed the Fortis team, believing that the corporate environment will boost patient-centric care and infrastructural needs. The complete takeover process is expected to be completed within two months, as stated by Ashish Bhatia, Executive Vice-President of Fortis Healthcare. With this acquisition, Fortis Healthcare strengthens its presence in Punjab, providing high-quality healthcare services to a wider population.
Biocon Ltd (BOM:532523) Reports Strong Revenue Increase in Q1 2026 Earnings, Despite Margin Pressures, as Noted by GuruFocus on Investing.com Canada.
Biocon Ltd, an Indian biopharmaceutical company, reported its Q1 2026 earnings, showcasing strong revenue growth despite margin pressures. Here are the highlights from the earnings call:
Revenue Growth: Biocon Ltd posted a robust revenue growth of 23% year-over-year (YoY) to ₹2,441 crores ($310 million USD), driven by a strong performance across its business segments. The company’s biologics segment witnessed a significant growth of 31% YoY, while the small molecule segment grew by 18% YoY.
Margin Pressure: Despite the strong revenue growth, Biocon’s margins faced pressure due to higher research and development (R&D) expenses, which increased by 34% YoY to ₹351 crores ($45 million USD). The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) margin contracted by 200 basis points to 24.1%, primarily due to the increased R&D expenses.
Operational Highlights: Biocon’s biologics segment received a significant boost with the European Commission’s approval for its biosimilar, Semglee (insulin glargine), in the European Union. The company also received approval from the US FDA for its Abraxane (paclitaxel) formulation. These approvals are expected to drive future growth for the company.
Guidance: Biocon Ltd maintained its fiscal year 2026 revenue growth guidance of 15-18% YoY, despite the short-term margin pressures. The company expects its biologics segment to drive growth, with a focus on expanding its global footprint.
Management Commentary: During the earnings call, the management team expressed confidence in the company’s long-term growth prospects, driven by its robust pipeline of biosimilars and small molecule products. They acknowledged the short-term margin pressures but emphasized that these are necessary investments for future growth.
Investor Takeaway: Biocon Ltd’s Q1 2026 earnings call highlights the company’s strong revenue growth trajectory, driven by its biologics segment. While margin pressures are a near-term concern, the company’s long-term growth prospects remain intact. Investors should focus on the company’s ability to execute on its pipeline and expand its global footprint, which will drive future growth and profitability. With a strong financial position and a robust pipeline, Biocon Ltd is well-positioned to navigate the challenges and opportunities in the biopharmaceutical industry.
ZDS-Varenicline, a smoking cessation medication developed by Zydus Lifesciences, receives approval from Health Canada, as reported by geneonline.com.
Zydus Lifesciences, a leading pharmaceutical company, has received approval from Health Canada for its smoking cessation drug, ZDS-Varenicline. This approval marks a significant milestone for the company, as it expands its presence in the Canadian market. ZDS-Varenicline is a generic version of Pfizer’s Chantix, which is a well-established medication for helping smokers quit.
ZDS-Varenicline is a prescription medication that works by reducing cravings for smoking and blocking the pleasurable effects of smoking. It is a selective alpha4beta2 nicotinic receptor partial agonist, which means it targets specific receptors in the brain that are involved in nicotine addiction. By activating these receptors, ZDS-Varenicline reduces the desire to smoke and helps individuals manage withdrawal symptoms.
The approval of ZDS-Varenicline by Health Canada is based on a comprehensive review of the drug’s safety and efficacy. Clinical trials have demonstrated that ZDS-Varenicline is effective in helping smokers quit, with studies showing that it can increase the chances of quitting by up to 50% compared to placebo. The medication has also been shown to be well-tolerated, with common side effects including nausea, insomnia, and headache.
Zydus Lifesciences’ approval for ZDS-Varenicline is a significant development for smokers in Canada who are looking to quit. Smoking is a major public health concern, and nicotine addiction is a significant challenge for many individuals. The availability of an affordable and effective generic medication like ZDS-Varenicline can help increase access to treatment and improve health outcomes for Canadians.
The company’s CEO, Sharvil Patel, expressed his excitement about the approval, stating that it reinforces the company’s commitment to providing high-quality and affordable medications to patients. Zydus Lifesciences has a strong presence in the Canadian market, and the approval of ZDS-Varenicline is expected to further expand its portfolio of medications.
In conclusion, the approval of ZDS-Varenicline by Health Canada is a significant achievement for Zydus Lifesciences, marking a major milestone in the company’s expansion into the Canadian market. The availability of this generic smoking cessation medication is expected to provide a more affordable treatment option for Canadian smokers, helping them to overcome nicotine addiction and improve their overall health. With its proven safety and efficacy, ZDS-Varenicline is poised to make a positive impact on public health in Canada.
Burn Pain Treatment Industry: Research, Therapies, and Key Players Including Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, and Trio Li.
The burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. According to DelveInsight, the market is driven by the rising demand for effective pain management therapies for burn patients. Burn pain is a complex and debilitating condition that can have a significant impact on a patient’s quality of life. The market is witnessing the emergence of new therapies and treatments that aim to provide relief to patients suffering from burn pain.
The epidemiology of burn pain is a significant concern, with millions of people suffering from burn injuries every year. The majority of burn injuries are minor, but a significant proportion require medical attention. The global burn pain market is expected to grow due to the increasing incidence of burn injuries, particularly in developing countries where access to healthcare is limited.
Several companies are actively involved in the development of burn pain therapies, including Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, and Trio Life Sciences. These companies are investing heavily in research and development to create innovative treatments for burn pain. For example, Johnson & Johnson is developing a new topical cream for the treatment of burn pain, while Pfizer Inc. is working on a novel oral medication.
The current treatment landscape for burn pain is dominated by analgesics, such as morphine and fentanyl, which are often ineffective in managing severe burn pain. However, new therapies are emerging, including topical creams, dressings, and other innovative treatments. For instance, Mankind Pharma has developed a new dressing that helps to reduce pain and promote wound healing.
The burn pain market is expected to grow significantly over the next few years, driven by the increasing demand for effective pain management therapies. The market is also witnessing the emergence of new companies, such as Trio Life Sciences, which is developing a novel burn pain treatment. Sun Pharmaceutical Industries Ltd is also investing heavily in research and development to create innovative treatments for burn pain.
In conclusion, the burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. The market is driven by the rising demand for effective pain management therapies, and several companies are actively involved in the development of new treatments. The current treatment landscape is dominated by analgesics, but new therapies are emerging, including topical creams, dressings, and other innovative treatments. As the market continues to grow, it is expected to provide relief to millions of patients suffering from burn pain worldwide.
CureVac and GSK have reached an agreement to settle their ongoing patent dispute with Pfizer and BioNTech.
CureVac, a German biotechnology company, and GlaxoSmithKline (GSK) have agreed to resolve a patent dispute litigation with Pfizer and BioNTech related to COVID-19 vaccine technology. The dispute centered on the use of messenger RNA (mRNA) technology, which is a key component of many COVID-19 vaccines, including those developed by Pfizer and BioNTech.
CureVac had alleged that Pfizer and BioNTech had infringed on its patents related to mRNA technology, which CureVac had developed prior to the pandemic. The company had sought damages and an injunction to prevent further use of its patented technology. Pfizer and BioNTech had denied any wrongdoing and argued that their vaccines did not infringe on CureVac’s patents.
The settlement marks the end of a long-running dispute between the companies. While the terms of the settlement have not been disclosed, it is likely that CureVac will receive some form of compensation or royalty payments from Pfizer and BioNTech. The settlement also removes a major uncertainty for the companies involved and allows them to focus on their ongoing vaccine development and distribution efforts.
Notably, BioNTech recently acquired a stake in CureVac, which likely played a role in the settlement. The acquisition gives BioNTech access to CureVac’s mRNA technology and expertise, and may have helped to facilitate a resolution to the patent dispute. The settlement is also a positive development for GSK, which had partnered with CureVac to develop a COVID-19 vaccine.
The resolution of the patent dispute is a significant development in the COVID-19 vaccine landscape. The use of mRNA technology has been a key factor in the rapid development and distribution of COVID-19 vaccines, and the settlement ensures that this technology can continue to be used to combat the pandemic. The settlement also highlights the complex and often contentious nature of patent disputes in the biotechnology industry, where intellectual property rights are highly valued and closely guarded.
Overall, the settlement between CureVac, GSK, Pfizer, and BioNTech is a positive development that removes a major obstacle to the ongoing development and distribution of COVID-19 vaccines. The settlement allows the companies involved to focus on their core business and underscores the importance of collaboration and cooperation in the fight against the pandemic.
The Steroid Implant Market is Expected to Experience Significant Growth, with Key Players such as Novartis, Allergan, and Pfizer Driving the Trend.
The Global Steroid Implant Market Study, conducted by HTF Market Intelligence, provides a comprehensive analysis of the market from 2025 to 2033. The report spans over 143 pages and covers the product and industry scope, market prognosis, and status. The market is expected to expand at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2033, from USD 0.65 billion in 2025 to USD 1.51 billion by 2033.
The study segments the market by type, including dexamethasone, fluocinolone acetonide, prednisolone, methylprednisolone, and biodegradable. The market is also segmented by application, including ophthalmology, pain management, hormone replacement, chronic inflammation, and post-surgery care.
The dominant region in the market is North America, while the fastest-growing region is Asia-Pacific. The market trends include ocular, orthopedic, and dermatological applications, biodegradable and sustained-release platforms, personalized implant formulations, and drug-device combination therapies.
The market drivers include growth in chronic disease management, preference for long-acting therapies, advancements in biocompatible polymers, and a rise in outpatient/minimally invasive procedures. However, the market faces challenges such as implant rejection or infection risks, cost-intensive development, device failure or drug leakage issues, slow regulatory pathways, and the need for surgical expertise in some cases.
The market opportunities include expansion in veterinary applications, innovation in biosimilar implants, integration with remote monitoring, regulatory easing for targeted therapies, and partnerships with specialty clinics. Major companies profiled in the Steroid Implant Market include Allergan, Bayer, Novartis, Bausch Health, and Pfizer, among others.
The report provides a comprehensive analysis of the market, including in-depth analysis of market segments, regional analysis, and competitive analysis. It also provides insights into the market trends, drivers, challenges, and opportunities. The report is available for purchase, and a sample copy can be requested.
The key findings of the report include:
* The global Steroid Implant market is expected to expand at a CAGR of 11.3% from 2025 to 2033.
* The market is driven by growth in chronic disease management, preference for long-acting therapies, and advancements in biocompatible polymers.
* The market faces challenges such as implant rejection or infection risks, cost-intensive development, and slow regulatory pathways.
* The market opportunities include expansion in veterinary applications, innovation in biosimilar implants, and integration with remote monitoring.
Overall, the report provides a comprehensive analysis of the Global Steroid Implant Market, including market trends, drivers, challenges, and opportunities. It is a valuable resource for companies, investors, and researchers seeking to understand the market and make informed decisions.
Delhi High Court Grants Sun Pharma Reprieve by Restraining Use of BERIVITAL, BEZOLIC, and DOZE-30 Due to Trademark Infringement
The Delhi High Court has granted relief to Sun Pharma, a prominent pharmaceutical company, by barring the use of three trademarks – BERIVITAL, BEZOLIC, and DOZE-30 – due to trademark infringement. This decision is a significant victory for Sun Pharma, as it protects the company’s intellectual property rights and prevents other companies from using similar trademarks that could cause confusion among consumers.
The court’s ruling is based on the principle that a trademark is a unique identifier of a company’s products or services, and its use by another company can lead to confusion and dilution of the brand. In this case, the defendants were found to be using trademarks that were similar to Sun Pharma’s registered trademarks, which could have caused harm to the company’s reputation and business.
The Delhi High Court’s decision highlights the importance of protecting intellectual property rights, particularly in the pharmaceutical industry where brand reputation and trust are crucial. The court’s ruling sends a strong message to companies that attempt to infringe on registered trademarks, and it demonstrates the court’s commitment to upholding the law and protecting the rights of legitimate trademark owners.
The trademarks in question, BERIVITAL, BEZOLIC, and DOZE-30, are likely to be associated with specific products or therapies, and the court’s decision ensures that Sun Pharma’s products will not be confused with those of other companies. This decision also reinforces the importance of conducting thorough trademark searches and clearance procedures before launching new products or services.
Overall, the Delhi High Court’s decision is a significant win for Sun Pharma, and it demonstrates the company’s commitment to protecting its intellectual property rights. The ruling also serves as a reminder to other companies to respect the trademark rights of others and to take necessary steps to avoid infringement. By protecting its trademarks, Sun Pharma can maintain its brand integrity and continue to provide high-quality products to its customers without fear of confusion or dilution.
Pfizer’s CEO is set to attend a $25 million fundraising event hosted at one of Donald Trump’s golf courses, despite the President’s recent calls for the pharmaceutical company to lower its drug prices, according to sources.
Pfizer CEO Albert Bourla is expected to attend a fundraiser for President Trump’s super PAC, MAGA Inc., at his golf club in Bedminster, New Jersey. The event aims to raise $25 million. However, the meeting comes at an interesting time, as President Trump has been putting pressure on pharmaceutical companies, including Pfizer, to lower drug prices in the US. Just a day before the fundraiser, the President sent letters to 17 drug companies, including Pfizer, demanding that they lower prices to match those in other countries.
The letters asked the companies to commit to selling drugs at “most favored nation” rates, which would mean that the US would pay the same price as the country with the lowest price for a particular drug. The President has been pushing for this change, signing an executive order in May that told federal officials to draw up regulations to achieve this goal unless the pharmaceutical companies made progress on their own.
President Trump has been vocal about his efforts to lower drug prices, saying that he has “gone to war” with the pharmaceutical companies and other countries on the issue. He claims that he will be successful in bringing down prices by as much as 1,200 percent. The high cost of prescription drugs has been a long-standing issue in the US, with both parties proposing solutions over the years.
The pharmaceutical industry has pushed back against the idea of price caps, arguing that they could discourage innovation and make it harder to fund research and development for new drugs. However, the President is determined to make a change, and his meeting with Bourla and other pharmaceutical executives will likely be closely watched.
Bourla has a history of engaging with President Trump, having worked with him on the development of COVID-19 vaccines through the “Operation Warp Speed” program. He also met with the President at Mar-A-Lago two weeks before his second inauguration. The meeting between the two will be interesting, given the President’s recent demands for lower drug prices. CBS News has reached out to Pfizer and the White House for comment on the matter.
Fortis Hospital ordered to compensate Rs 50 lakh for medical negligence
The District Consumer Disputes Redressal Commission in Chandigarh has held Fortis Hospital in Mohali and one of its doctors guilty of medical negligence. The commission has ordered the hospital to pay a compensation of Rs 50 lakh along with 9% interest per annum to the widow of a patient who died during treatment. The patient, Harit Sharma, was admitted to the hospital in 2021 with an acute gastric problem. Despite initial improvement, his condition deteriorated due to alleged negligence in a medical procedure called tapping, which was done to remove ascites from his stomach.
The patient’s wife, Priyanka Sharma, filed a complaint with the commission, alleging that the hospital staff was negligent in performing the tapping procedure, which led to a drastic drop in her husband’s oxygen levels. She claimed that her husband was fully conscious and aware of the mistake made by the hospital staff, and he even wrote a note to her conveying what had happened during the procedure. Unfortunately, Harit Sharma passed away on August 2, 2021.
The hospital authorities refuted the allegations, claiming that there was no negligence on their part and that there was no expert evidence to prove otherwise. However, the commission found the hospital liable for medical negligence, deficiency in service, and unfair trade practice. The commission ordered the hospital to pay a lump sum compensation of Rs 50 lakh along with 9% interest per annum from the date of the patient’s death.
The commission’s decision was based on the fact that the hospital had failed to provide adequate care and treatment to the patient, leading to his death. The commission also took into account the dying declaration made by the patient, which provided evidence of the hospital’s negligence. The order highlights the importance of hospitals and medical professionals providing adequate care and treatment to patients, and the consequences of failing to do so. The case serves as a reminder of the need for accountability and transparency in the medical profession.
Natco Pharma names TC Mallikarjun as its new Vice President.
Natco Pharma, a leading pharmaceutical company, has announced the appointment of TC Mallikarjun as Vice President – Quality Control (QC) at its Kothur Pharma Division. This appointment is a significant development for the company, as it continues to strengthen its leadership team and enhance its quality control capabilities.
TC Mallikarjun brings a wealth of experience and expertise in quality control to Natco Pharma. His appointment is expected to play a key role in ensuring the highest standards of quality in the company’s pharmaceutical products. As Vice President – QC, Mallikarjun will be responsible for overseeing the quality control operations at the Kothur Pharma Division, which is one of the company’s key manufacturing facilities.
The appointment of TC Mallikarjun is a testament to Natco Pharma’s commitment to quality and excellence. The company has a strong reputation for producing high-quality pharmaceutical products, and this appointment is expected to further reinforce this reputation. Mallikarjun’s expertise and leadership will be instrumental in ensuring that the company’s products meet the highest standards of quality, safety, and efficacy.
Natco Pharma’s Kothur Pharma Division is a state-of-the-art manufacturing facility that produces a wide range of pharmaceutical products. The division is equipped with cutting-edge technology and infrastructure, and is staffed by a team of experienced professionals who are committed to producing high-quality products. With TC Mallikarjun at the helm of quality control, the division is expected to continue to produce products that meet the highest standards of quality and excellence.
The appointment of TC Mallikarjun is also a reflection of Natco Pharma’s commitment to attracting and retaining top talent. The company has a strong track record of attracting experienced professionals who are passionate about producing high-quality pharmaceutical products. Mallikarjun’s appointment is expected to be a significant addition to the company’s leadership team, and is expected to contribute to the company’s continued success and growth.
Overall, the appointment of TC Mallikarjun as Vice President – QC at Natco Pharma’s Kothur Pharma Division is a significant development for the company. It reflects the company’s commitment to quality, excellence, and attracting top talent, and is expected to play a key role in ensuring the highest standards of quality in the company’s pharmaceutical products.
Future Female Forward | Apollo HealthCo’s Shobana Kamineni: ‘We’re aiming for a phenomenal, blockbuster demerger’
Shobana Kamineni, Executive Chairperson of Apollo HealthCo, has made a bold prediction that the company’s turnover will soon surpass that of Apollo Hospitals. This statement was made at the CNBC-TV18’s Future Female Forward event in Bengaluru, where Kamineni emphasized the company’s trajectory towards digital healthcare and retail pharmacy. Apollo HealthCo is a subsidiary of Apollo Hospitals Enterprise Ltd, established after a demerger that separated the digital healthcare platform Apollo 24/7 and the retail pharmacy business into a distinct entity.
The demerger is part of a broader plan to raise external capital and achieve substantial growth. Apollo HealthCo aims to reach 100 million registered users and a revenue target of ₹12,000 crore within four years, with the goal of becoming a leader in India’s digital healthcare landscape. To achieve this, the company has received significant investments, including a $300 million infusion from Advent International. This investment is expected to fuel the growth of Apollo 24/7 and the pharma distribution business, with expectations to increase EBITDA from 1.5% to 7-8% as the digital healthcare business completes its investment phase.
Kamineni’s prediction suggests a transformative shift towards digital healthcare and retail pharmacy within the Apollo Group. The company’s expansion plans are ambitious, with a target to double its turnover to ₹25,000 crore by FY27. Apollo HealthCo’s growth is expected to be driven by the increasing demand for digital healthcare services and the company’s ability to leverage technology to provide convenient and accessible healthcare solutions.
The investment from Advent International is a significant boost to Apollo HealthCo’s expansion plans. The company plans to use the funds to enhance its digital healthcare platform, expand its retail pharmacy business, and increase its market reach. With a strong focus on digital healthcare and retail pharmacy, Apollo HealthCo is well-positioned to become a leading player in India’s healthcare industry. Kamineni’s prediction of surpassing Apollo Hospitals’ turnover is a testament to the company’s growth potential and its commitment to revolutionizing the healthcare landscape in India.
Fortis and Agilus Enhance Genomic Testing Capabilities with Additional Genexus System, Accelerating Cancer Diagnosis.
Fortis and Agilus have partnered to enhance genomic testing capabilities with the installation of a second Genexus system. This move is expected to significantly improve the speed and accuracy of cancer diagnosis. The Genexus system is a next-generation sequencing (NGS) platform that enables comprehensive genomic profiling, allowing for the analysis of multiple genes and biomarkers in a single test.
The addition of a second Genexus system will increase Fortis’s testing capacity, enabling the processing of a higher volume of samples and reducing turnaround times. This is particularly crucial in cancer diagnosis, where timely and accurate results are essential for guiding treatment decisions. With the enhanced capacity, Fortis and Agilus aim to provide faster and more accurate diagnosis, ultimately improving patient outcomes.
The Genexus system offers several advantages, including its ability to analyze multiple genes and biomarkers simultaneously, reducing the need for multiple tests and minimizing tissue requirements. This comprehensive approach enables the identification of genetic mutations and variations that can inform treatment strategies, including targeted therapies and immunotherapies.
The partnership between Fortis and Agilus is built on a shared commitment to improving cancer diagnosis and treatment. Agilus, a leading provider of genetic testing solutions, has developed the Genexus system to address the growing need for advanced genomic testing. Fortis, a prominent healthcare provider, has recognized the potential of the Genexus system to enhance its diagnostic capabilities and has invested in the technology to improve patient care.
The installation of the second Genexus system is a significant milestone in the partnership between Fortis and Agilus. It demonstrates their shared commitment to leveraging cutting-edge technology to improve cancer diagnosis and treatment. With the enhanced genomic testing capabilities, Fortis and Agilus are poised to make a meaningful impact on patient care, enabling faster and more accurate diagnosis, and ultimately improving treatment outcomes.
In conclusion, the partnership between Fortis and Agilus has resulted in the installation of a second Genexus system, strengthening their genomic testing capabilities and enabling faster cancer diagnosis. The enhanced capacity and accuracy of the Genexus system will have a significant impact on patient care, providing timely and accurate results that can inform treatment decisions. As the demand for advanced genomic testing continues to grow, the collaboration between Fortis and Agilus is well-positioned to drive innovation and improve patient outcomes in the field of cancer diagnosis and treatment.
Zydus Lifesciences Limited (ZYDUSLIFE) Ventures into Uncharted Territory with Lucrative Investment Opportunities – PrintWeekIndia
Zydus Lifesciences Limited, a leading pharmaceutical company, has announced its expansion into a new market, marking a significant milestone in its growth journey. This strategic move is expected to open up new avenues for revenue growth and increase the company’s global footprint.
The new market expansion is a high-profit capital play, indicating that the company has identified a lucrative opportunity to tap into a growing demand for pharmaceutical products. This move is expected to generate significant revenue and profitability for Zydus Lifesciences, enabling the company to further invest in its research and development capabilities, expand its product portfolio, and strengthen its position in the global pharmaceutical market.
Zydus Lifesciences has a strong track record of innovation and has developed a robust portfolio of pharmaceutical products that cater to a wide range of therapeutic segments. The company’s expansion into the new market is expected to leverage its existing strengths and capabilities, including its manufacturing infrastructure, research and development expertise, and distribution networks.
The company’s management has expressed confidence in the potential of the new market and has outlined a clear strategy for expansion. The plan includes establishing a strong distribution network, building relationships with local partners and stakeholders, and launching a range of products that are tailored to meet the specific needs of the new market.
The expansion into the new market is also expected to provide Zydus Lifesciences with an opportunity to diversify its revenue streams and reduce its dependence on any one market or product. This will enable the company to mitigate risks and increase its resilience to market fluctuations, while also providing a platform for long-term growth and sustainability.
Overall, the expansion of Zydus Lifesciences into the new market is a significant development that is expected to have a positive impact on the company’s financial performance and growth prospects. The company’s strong track record of innovation, its robust product portfolio, and its clear strategy for expansion make it well-placed to capitalize on the opportunities presented by the new market. As the company continues to execute its growth plans, it is likely to remain a key player in the global pharmaceutical market, with a strong focus on delivering value to its stakeholders and improving the lives of patients around the world.
The move is expected to increase the profitability of the company, with the company’s management expressing confidence in the potential of the new market. With a strong distribution network, research and development expertise, and a range of products, Zydus Lifesciences is well-placed to capitalize on the opportunities presented by the new market. The company’s expansion into the new market is a significant development that is expected to have a positive impact on the company’s financial performance and growth prospects.
Piramal Pharma Limited (PPLPHARMA) is poised for a profitable breakthrough in 2025, according to Autocar Professional.
Piramal Pharma Limited (PPL) is expected to continue its upward trend in 2025, driven by breakthrough profits in the pharmaceutical sector. The company has been making significant strides in the industry, with a focus on innovation, research, and development. Here are the key highlights of PPL’s expected trend in 2025:
Strong Financial Performance: PPL is anticipated to report strong financial performance in 2025, with significant revenue growth and improved profitability. The company’s revenue is expected to increase by 15-20% year-on-year, driven by the growth of its pharmaceutical business. Net profit is also expected to rise by 20-25% year-on-year, driven by improved operating margins and efficient cost management.
Driving Factors: Several factors are expected to drive PPL’s growth in 2025. These include:
- Innovation: PPL has been investing heavily in research and development, with a focus on developing new and innovative products. This is expected to drive growth in the company’s pharmaceutical business.
- Expansion into new markets: PPL is expected to expand its presence in new markets, including emerging economies and developed markets. This is expected to provide new growth opportunities for the company.
- Strategic partnerships: PPL is expected to form strategic partnerships with other companies to drive growth and improve its competitive position.
Pharmaceutical Business: PPL’s pharmaceutical business is expected to be a key driver of growth in 2025. The company has a strong portfolio of products, including prescription and over-the-counter drugs. PPL is also expected to launch new products in 2025, which will help drive growth in the pharmaceutical business.
Growth Outlook: PPL’s growth outlook for 2025 is positive, driven by the company’s strong financial performance, innovative products, and expansion into new markets. The company is expected to continue to invest in research and development, which will help drive growth in the long term.
Challenges: Despite the positive growth outlook, PPL is expected to face several challenges in 2025. These include intense competition in the pharmaceutical industry, regulatory challenges, and pricing pressure. However, the company is well-positioned to overcome these challenges, given its strong financial performance and innovative products.
Overall, Piramal Pharma Limited is expected to continue its upward trend in 2025, driven by breakthrough profits in the pharmaceutical sector. The company’s strong financial performance, innovative products, and expansion into new markets are expected to drive growth in the long term. While there are challenges ahead, PPL is well-positioned to overcome them and achieve its growth objectives.
Sun Pharma Reports Favorable Phase 3 Trial Outcomes for Tildrakizumab in Treating Psoriatic Arthritis
Sun Pharma has announced positive top-line results from two phase 3 clinical trials, INSPIRE-1 and INSPIRE-2, evaluating the efficacy and safety of tildrakizumab 100 mg (Ilumya) in patients with active psoriatic arthritis. The studies, which enrolled over 800 patients, met their primary endpoint, demonstrating significant improvements in psoriatic arthritis signs and symptoms compared to placebo after 24 weeks of treatment.
Tildrakizumab, a high-affinity humanized immunoglobulin antibody, targets the p19 subunit of IL-23 and has been previously approved for the treatment of plaque psoriasis in patients who are candidates for systemic therapy or phototherapy. The INSPIRE-1 and INSPIRE-2 studies were designed to assess the efficacy and safety of tildrakizumab in patients with active psoriatic arthritis, with patients randomized to receive either tildrakizumab 100 mg or placebo.
The primary endpoint of the studies was the proportion of participants achieving an American College of Rheumatology 20% response criteria (ACR20) at Week 24, which was met in both INSPIRE-1 and INSPIRE-2. Secondary efficacy endpoints at 24 weeks included ACR50, ACR70, and Psoriasis Area Severity Index (PASI) 75. The safety data observed in the studies aligns with the well-documented safety profile of tildrakizumab for moderate-to-severe plaque psoriasis.
According to Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma, “These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis.” The company plans to present the full results at upcoming conferences and publish them in a peer-reviewed medical journal.
The findings support the potential regulatory submission of Ilumya for the treatment of active psoriatic arthritis in the US. Tildrakizumab is also being evaluated for the treatment of stable nonsegmental vitiligo. The positive results from the INSPIRE-1 and INSPIRE-2 studies demonstrate the potential of tildrakizumab as a treatment option for patients with active psoriatic arthritis, and further research is needed to fully understand its efficacy and safety in this patient population.
Overall, the announcement from Sun Pharma highlights the potential of tildrakizumab as a treatment option for patients with active psoriatic arthritis, and the company’s commitment to advancing the development of this therapy for patients in need. The results of the INSPIRE-1 and INSPIRE-2 studies are a significant step forward in the treatment of psoriatic arthritis, and further research is expected to provide additional insights into the efficacy and safety of tildrakizumab in this patient population.
Cipla’s CEO responds to tariff threats, highlighting the company’s diversified business model as a key strength.
Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla’s CEO, Umang Vohra, emphasized that the company has “one of the most well-diversified models” in the industry, which would help mitigate the effects of tariff changes.
Vohra explained that Cipla’s diversified portfolio, which includes a mix of domestic and international businesses, would cushion the company from the potential fallout of tariffs. The company has a significant presence in various markets, including the US, Europe, and emerging markets, which would help spread the risk. Additionally, Cipla has a diversified product portfolio, with a range of therapies and products, including respiratory, cardiac, and anti-infective medicines.
The CEO also highlighted Cipla’s strong manufacturing capabilities, which would enable the company to adapt to changes in tariffs. Cipla has a robust manufacturing network, with facilities in India, the US, and other countries, which would allow the company to shift production to other locations if needed. This flexibility would help minimize the impact of tariffs on the company’s operations.
Vohra noted that while tariffs are a concern, they are not a new challenge for the company. Cipla has been navigating tariff changes and other trade-related issues for many years and has developed strategies to manage these risks. The company has a strong track record of adapting to changing market conditions and has a robust risk management framework in place.
Cipla’s diversified model and strong manufacturing capabilities have enabled the company to deliver consistent growth and performance, despite the challenges posed by tariffs and other factors. The company has reported strong revenue growth in recent quarters, driven by its domestic and international businesses.
In conclusion, Cipla’s CEO, Umang Vohra, is confident that the company’s diversified model and strong manufacturing capabilities would help mitigate the impact of tariff threats. With a diversified portfolio, robust manufacturing network, and strong risk management framework, Cipla is well-positioned to navigate the challenges posed by tariffs and other trade-related issues. The company’s consistent growth and performance demonstrate its ability to adapt to changing market conditions, and it is likely to continue to deliver strong results in the future. Overall, Cipla’s diversified model and strong manufacturing capabilities make it a resilient and attractive investment opportunity.
Global Digoxin Industry Analysis: An In-Depth Report Featuring Key Players Such as Pfizer, Novartis, and Mylan
The Global Digoxin Market study, recently introduced by HTF MI, provides a comprehensive overview of the product and industry scope, as well as an in-depth analysis of the market outlook and status from 2025 to 2031. The market is segmented by key regions, including North America, South America, Europe, Asia Pacific, and the Middle East and Africa.
The global Digoxin market was valued at USD 1.5 billion in 2024 and is expected to reach USD 2.4 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 6.1% from 2025 to 2031. The market is driven by the increasing prevalence of heart conditions, such as atrial fibrillation and congestive heart failure, particularly in aging populations. Technological advancements in cardiac monitoring and diagnostics have also enabled more precise dosage and monitoring of digoxin.
The major companies operating in the Digoxin market include Pfizer Inc., Merck & Co., Inc., Cipla Limited, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., and Lupin Limited.
The market is segmented by application (tablet product and injection product) and by type (purity above 98% and purity below 98%). North America is the dominating region, while Asia-Pacific is the fastest-growing region. The market is expected to grow due to the increasing demand for digoxin in emerging markets, investments in healthcare infrastructure, and the development of digital health tools for drug monitoring and adherence.
However, the market is also restrained by the availability of alternative treatments, adverse drug reactions, and stringent regulatory guidelines. The major challenges facing the market include side effects, such as digoxin toxicity, and complex interactions with other medications.
The report provides an in-depth analysis of the market, including a five-forces analysis and a PESTLE analysis, which examines the political, economic, social, technological, legal, and environmental factors affecting the market. The report also provides a detailed analysis of the market segmentation, competitive analysis, and market structure and worth analysis.
Overall, the Global Digoxin Market study provides a comprehensive overview of the market, including its drivers, restraints, challenges, and opportunities. The report is an essential resource for companies operating in the Digoxin market, as well as for investors, researchers, and policymakers.
Key Takeaways:
– The global Digoxin market is expected to reach USD 2.4 billion by 2031, with a CAGR of 6.1% from 2025 to 2031.
– The market is driven by the increasing prevalence of heart conditions and technological advancements in cardiac monitoring and diagnostics.
– North America is the dominating region, while Asia-Pacific is the fastest-growing region.
– The market is restrained by the availability of alternative treatments, adverse drug reactions, and stringent regulatory guidelines.
– The report provides an in-depth analysis of the market, including a five-forces analysis and a PESTLE analysis.
Market Size:
– Global Digoxin market size was valued at USD 1.5 billion in 2024.
– Expected to reach USD 2.4 billion by 2031.
– CAGR of 6.1% from 2025 to 2031.
Segmentation:
– By Application: Tablet product and injection product.
– By Type: Purity above 98% and purity below 98%.
– By Geography: North America, South America, Europe, Asia Pacific, and the Middle East and Africa.
Key Players:
– Pfizer Inc.
– Merck & Co., Inc.
– Cipla Limited
– F. Hoffmann-La Roche Ltd.
– Abbott Laboratories
– Novartis AG
– Mylan N.V.
– Teva Pharmaceutical Industries Ltd.
– Dr. Reddy’s Laboratories Ltd.
– Lupin Limited.
Regional Analysis:
– North America
– South America
– Europe
– Asia Pacific
– Middle East and Africa.
The five forces analysis includes:
– Bargaining power of buyers
– Bargaining power of suppliers
– Threat of new entrants
– Threat of substitutes
– Threat of rivalry.
The PESTLE analysis includes:
– Political
– Economic
– Social
– Technological
– Legal
!- Environmental.
Nourishment comes first for optimal well-being
The importance of food in maintaining overall health and wellbeing has been emphasized for centuries. As stated in the ancient Sanskrit text, Charaka Samhita, “Annam hi jeevanam” or “food is life itself”. This phrase was recently quoted by Dr. Anupam Sibal, Group Medical Director of Apollo Hospitals, who highlighted the significance of food in sustaining life, energy, and consciousness. According to Dr. Sibal, food is not just a source of nourishment, but also plays a crucial role in maintaining health, preventing diseases, and promoting overall wellbeing.
The book, published by Penguin Random House India, addresses some of the most pressing health challenges facing the country today, including obesity, diabetes, hypertension, cardiovascular diseases, and cancers. These conditions are on the rise in India, and the book aims to provide a comprehensive guide to healthy eating and lifestyle choices. Dr. Sibal emphasized that eating healthy is not just about physical fitness or achieving a certain body size, but also about preventing chronic diseases, sharpening mental clarity, improving sleep quality, aging gracefully, and managing stress effectively.
The launch of the book marks the beginning of a larger movement towards promoting healthier choices and better nutrition across the nation. The goal is to empower individuals to make informed decisions about their diet and lifestyle, leading to a reduction in the incidence of lifestyle-related diseases. By emphasizing the importance of food in maintaining health and wellbeing, the book aims to inspire a cultural shift towards healthier eating habits and a more balanced lifestyle. Ultimately, the movement seeks to create a better-nourished nation, where individuals can thrive and live healthy, happy lives. With the book’s launch, the group hopes to inspire a new era of healthy eating and wellbeing in India, and to make a positive impact on the health and lives of individuals across the country.
Syngene Introduces its Third STEM Initiative Exclusively for Women in Collaboration with RICH and Biocon.
Syngene International Ltd., in partnership with Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, has launched the third cohort of its scholarship, mentoring, and industry orientation program for women in STEM (science, technology, engineering, and mathematics). The program aims to empower women from tier two and three institutions, providing them with structured mentorship, financial assistance, and hands-on research exposure. This year, 40 women students are participating in the program, which includes project-based internships with pharmaceutical and biotechnology companies, as well as government research institutions.
The program addresses the challenges faced by women from smaller cities in India, including inadequate exposure to scientific opportunities, financial limitations, and a shortage of mentors. By offering scholarships, personalized mentorship, and hands-on research experience, the program bridges the divide between academic knowledge and real-world career prospects. The program has grown into a strong career launchpad, benefiting over 50 women in the past two years.
The program’s impact is measurable, with participants gaining practical skills and confidence to shape their career paths. One participant, Revathi Karamalla, shared that the program helped her understand what a career in STEM looks like and provided her with the confidence to pursue her goals. Another participant, Abhirami K, expressed her excitement to gain new skills and grow through the experience.
The program has received praise from industry experts, including Dr. Parvinder Maini, Scientific Secretary, Office of the Principal Scientific Adviser, Government of India, who stated that the program is a regional solution model that connects science to society, talent to opportunity, and learning to livelihood. Dr. Anupama Narayan Shetty, Mission Director, Biocon Foundation, emphasized the importance of advancing equity in STEM and the program’s role in empowering talented women to pursue meaningful careers in science.
The program has shown significant growth and momentum, with the second cohort introducing new components such as a biotech industry visit and a national roundtable on Women in STEM. Several students have progressed to PhD programs, secured full-time research roles, or extended their internships, highlighting the program’s role in shaping research careers. The program’s success reinforces the importance of collaborative efforts between government, industry, and research institutions to promote equity and inclusion in science. Overall, the program is a critical step towards unlocking India’s full scientific potential and promoting inclusive opportunities for women in STEM.
Apollo Hospitals introduces a comprehensive nutrition guide to encourage proactive wellness.
Apollo Hospitals has launched a new book titled “My Food, My Health”, a comprehensive guide to combating lifestyle diseases through evidence-based nutrition. The book was released in Chennai and is designed to support preventive healthcare through nutrition therapy. The guide is authored by a team of senior dietitians, led by Anita Jatana, consultant dietetics at Indraprastha Apollo Hospitals.
The book is written in a reader-friendly format and offers practical advice on dietary strategies, meal plans, and nutrition tips. It also includes myth-busting facts, immunity-boosting tips, and recovery diets. The guide is supported by clinical insights, vibrant visuals, and easy-to-follow recipes, making it a valuable resource for patients, caregivers, and healthcare providers.
According to experts, the book provides a much-needed credible source of health information, addressing the growing concern of lifestyle diseases. The founder and chairman of Apollo Hospitals, Prathap C. Reddy, emphasized the importance of empowering people with accurate health information. He stated that “My Food, My Health” is a significant step towards creating a health-aware nation.
Anita Jatana, the lead author, highlighted the need for clarity on food and nutrition, citing the overwhelming amount of misinformation in the public domain. She emphasized that the book is rooted in clinical practice and is a collaborative effort of dieticians and nutritionists across the Apollo Group.
The book’s contributors include experts from Apollo Hospitals, ensuring that the information provided is evidence-based and trustworthy. The launch of “My Food, My Health” is a significant initiative by Apollo Hospitals to promote preventive healthcare and encourage individuals to take control of their health through informed nutrition choices. By providing a comprehensive guide to nutrition therapy, the book aims to empower readers to make informed decisions about their diet and lifestyle, ultimately contributing to a healthier nation.
Indian Court Dismisses Zydus Trastuzumab Lawsuit, Citing Lack Of Genuine Claim.
In a significant development, the Bombay High Court has dismissed a pre-emptive lawsuit filed by Indian pharmaceutical company Zydus Cadila against Swiss multinational company Roche nearly a decade ago. The lawsuit related to Zydus Cadila’s biosimilar version of Roche’s blockbuster cancer drug Herceptin. The court’s decision brings an end to a long-drawn-out legal battle that had been plagued by procedural delays.
Zydus Cadila had filed the pre-emptive complaint in an attempt to stave off potential litigation from Roche over its biosimilar Herceptin. However, the Bombay High Court has now ruled that Zydus Cadila’s complaint was an “illusion” of a real dispute, implying that there was no genuine controversy between the two parties. This decision suggests that Zydus Cadila’s lawsuit was premature and lacked substance.
The dispute centered around Zydus Cadila’s development of a biosimilar version of Herceptin, which is a monoclonal antibody used to treat certain types of breast cancer. Roche had been selling Herceptin globally, including in India, and had been seeking to protect its patent and intellectual property rights. Zydus Cadila, on the other hand, had been trying to launch its biosimilar version of the drug in the Indian market.
By filing the pre-emptive complaint, Zydus Cadila had hoped to gain a strategic advantage over Roche. However, the court’s decision has now dismissed this lawsuit, paving the way for Roche to potentially take action against Zydus Cadila’s biosimilar Herceptin. This could lead to further litigation between the two companies, with Roche seeking to protect its intellectual property rights and Zydus Cadila fighting to launching its biosimilar product.
The Indian pharmaceutical industry has been witnessing a surge in the development of biosimilars, which are cheaper versions of biologic drugs. The court’s decision in this case is likely to have significant implications for the industry, as it sets a precedent for how pre-emptive lawsuits will be treated in the future. The decision also highlights the complexities and challenges involved in intellectual property disputes in the pharmaceutical sector, particularly in the context of biosimilars.
Authorities with the DCA have seized counterfeit Levipil 500 tablets.
The Telangana State Drugs Control Administration (DCA) has cracked down on counterfeit medication in the region, seizing fake Levipil 500 tablets, which are used to treat epilepsy. The tablets were falsely labeled as products of Sun Pharma Laboratories Ltd, a reputable pharmaceutical company. The DCA’s special teams conducted raids at two locations: Arvind Pharma Distributors in Kavadiguda and Venu Medical Agencies in Karimnagar, where the counterfeit tablets were being distributed.
The raids took place on July 4 and 5, 2025, and the DCA was able to confirm the counterfeit status of the tablets by cross-checking them with Sun Pharma’s official records. The seizure of these fake tablets is a significant achievement for the DCA, as it helps to protect the public from the dangers of counterfeit medication. Counterfeit drugs can be ineffective, toxic, or even fatal, and it is essential to ensure that all medication is genuine and safe for consumption.
The DCA is now investigating the sources of the counterfeit tablets and will take legal action against those involved. The administration is also urging the public to report any suspicious drug production activities, including those involving narcotics and psychotropic substances, in any area. To facilitate this, the DCA has set up a toll-free number, 1800-599-6969, which is available from 10:30 am to 5 pm on weekdays. Citizens can use this number to report any illegal drug activities, and the DCA will take prompt action to address the issue.
The DCA’s efforts to combat counterfeit medication are crucial in ensuring the safety and well-being of the public. The administration’s actions demonstrate its commitment to protecting the health and welfare of the people of Telangana, and its efforts will help to prevent the spread of counterfeit medication in the region. By reporting suspicious activities and working together, the public and the DCA can help to create a safer and healthier environment for everyone.
Lupin Splits Off Its Consumer Healthcare Business to Form Independent Company
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate their consumer health operations from their prescription drug businesses. The goal is to better target the rapidly expanding self-care market in India. Anil Kaushal will lead the new subsidiary as CEO, bringing strategic focus and agility to Lupin’s consumer health portfolio.
The separation of the consumer healthcare business from the prescription drug business allows for more targeted investments and a dedicated approach to building strong consumer brands in the over-the-counter (OTC) space. Lupin’s OTC consumer healthcare business contributed ₹148 crore to the company’s total standalone revenue of ₹14,666 crore in FY24. The new subsidiary has a strong portfolio of scientifically formulated brands, including Softovac, Beplex Forte, Corcium, and Aptivate, which are positioned to leverage the rising demand for preventive healthcare and wellness in India.
The pharmaceutical sector is witnessing a trend of spinning off consumer health units, as companies recognize the need for separate business models to cater to prescription drugs and OTC healthcare products. This allows companies to streamline operations and adopt more FMCG-style promotion strategies tailored for consumer health products, while maintaining focus on their traditional pharma businesses. Companies such as Cipla, Glenmark, Mankind Pharma, and Sanofi have already adopted similar strategies.
The formation of LupinLife Consumer Healthcare Ltd reflects the company’s long-term vision of adapting to evolving healthcare needs and market dynamics in India. With this move, Lupin joins a broader industry shift that seeks to unlock value and accelerate growth in two distinct but complementary healthcare markets – prescription pharmaceuticals and consumer wellness products. The company’s move is expected to enable it to sharpen its focus on prescription drugs while allowing the OTC arm to thrive independently in a fast-growing and competitive consumer healthcare market.
Piramal Pharma Solutions initiates a $90 million expansion project in the United States.
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organisation (CDMO), has announced a $90 million investment plan to expand two of its US facilities. The expansion is aimed at enhancing the company’s integrated offering, particularly in the area of antibody-drug conjugate (ADC) therapies. The two sites involved in the expansion are located in Riverview, Michigan, and Lexington, Kentucky.
The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). The expansion at this site will add a commercial-scale suite for the development and manufacturing of payload-linkers, which are essential components of ADC therapies. The new suite is expected to be operational by the end of 2025.
The Lexington site is Piramal Pharma’s dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The expansion at this site will add commercial-scale sterile injectable manufacturing capabilities, including 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery. The expansion is expected to be completed by late 2027.
The investment is driven by the growing demand for sterile injectables, which is projected to exceed $20 billion by 2028. Piramal Pharma’s Chairperson, Nandini Piramal, expressed confidence that the expansion will enable the company to meet the demands of this market and reinforce its position as a trusted global partner in biologic manufacturing. The expansion is expected to enhance the services provided to partners, ultimately reducing the burden of disease for more patients around the globe.
The expansion is a strategic move by Piramal Pharma to strengthen its presence in the biologic manufacturing market. The company’s ADCelerate platform, which provides integrated services for ADC therapies, is expected to benefit from the expansion. The new facilities will provide Piramal Pharma with the capacity to develop and manufacture complex biologic products, including ADCs, and will enable the company to support its partners in bringing new therapies to market. Overall, the investment is a significant step forward for Piramal Pharma and is expected to have a positive impact on the company’s growth and reputation in the industry.
Pfizer and XtalPi Broaden Partnership to Accelerate AI-Powered Drug Development and Materials Science Research
XtalPi, a leading technology company, has announced an expansion of its research collaboration with Pfizer to develop a next-generation molecular modeling platform for drug discovery. The goal of this initiative is to improve the accuracy of advanced physics-based methods using cutting-edge AI models, with the aim of optimizing the discovery and development of small molecule medicines. The collaboration builds on the success of their existing strategic partnership, which has already demonstrated superior performance in predicting small molecule geometry and binding affinity.
The new platform, called XtalPi Force Field (XFF), will be designed to support Pfizer scientists across diverse drug design and development scenarios. XtalPi will deploy its XFEP platform, which includes parameter customization and FEP calculations, to enable Pfizer to use it in their drug discovery efforts. The platform will be designed to provide improved accuracy, high-throughput speed, and a user-friendly interface.
The collaboration between XtalPi and Pfizer has the potential to transform the field of drug discovery by unlocking new possibilities and accelerating the delivery of life-changing therapies for patients worldwide. According to Dr. Jian Ma, CEO of XtalPi, Pfizer’s leadership in pharmaceutical innovation and deep scientific expertise have been invaluable in shaping the evolution of XtalPi’s AI-driven platform.
XtalPi was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT) and is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. The company provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
The expansion of the collaboration between XtalPi and Pfizer is a significant development in the field of drug discovery, and it has the potential to lead to breakthroughs in the treatment of various diseases. With the use of advanced AI models and physics-based methods, the platform is expected to provide more accurate predictive tools and improve the efficiency of the drug discovery process. Overall, the collaboration between XtalPi and Pfizer is a promising development that could lead to the discovery of new and innovative medicines.
Rajkummar Rao appointed as the Brand Ambassador for Nimulid Strong by Mankind Pharma
Mankind Pharma, India’s fourth-largest pharmaceutical company, has appointed Rajkummar Rao as the brand ambassador for its flagship product, Nimulid Strong Pain Relief Gel & Spray. This move aims to strengthen the company’s position in the topical pain relief segment. Nimulid Strong is positioned as the “Neck Pain Specialist” due to its powerful 2X Diclofenac formulation, which delivers rapid relief in just two minutes.
The partnership between Mankind Pharma and Rajkummar Rao aligns with the brand’s promise of effective, localized relief and the actor’s relatable persona. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, expressed excitement about the collaboration, stating that Rajkummar’s authenticity and craft resonate deeply with the audience. Rajkummar Rao, known for his acclaimed performances in various films, shared his enthusiasm about endorsing Nimulid Strong, citing its promise of quick relief for neck pain as a game-changer.
Nimulid Strong has already made a strong debut in the topical pain relief market, valued at ₹5,000 crore, with over ₹15 crore in sales and approximately 30 lakh units sold in its first year. The product features a potent 2.32% Diclofenac formulation, delivering faster and deeper relief from neck pain, stiffness, and inflammation. Available in gel and spray formats, Nimulid Strong offers long-lasting and on-the-go solutions tailored for today’s digitally fatigued and posture-stressed generation.
Mankind Pharma plans to expand the product line to include balms, roll-ons, and tablets, with a focus on innovation and accessibility. The company is committed to addressing modern pain challenges such as tech neck, work-from-home strain, and sedentary fatigue, helping consumers return to their routines without disruption. By partnering with Rajkummar Rao, Mankind Pharma aims to empower individuals to overcome pain-related challenges and lead pain-free lives.
With Nimulid Strong, Mankind Pharma is poised to take a leading position in the topical pain relief segment. The company’s commitment to innovation, accessibility, and effective pain relief solutions is expected to resonate with consumers, particularly in the digitally driven and fast-paced world of today. As Rajkummar Rao advocates for Nimulid Strong, the brand is likely to reach a wider audience and reinforce its position as a trusted and reliable solution for neck pain and other related issues.
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company’s plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in only one Form 483 observation. A Form 483 is a document issued by the US FDA to notify a company of any objections or concerns related to their manufacturing processes or facilities.
The fact that NATCO Pharma’s plant received only one Form 483 observation is a significant achievement, as it indicates that the company’s quality control and manufacturing processes are in compliance with US FDA regulations. The observation is considered minor and is not expected to have a significant impact on the company’s operations or their ability to export products to the US market.
NATCO Pharma’s Hyderabad plant is a key manufacturing facility for the company, producing a range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosages. The plant has been inspected by the US FDA several times in the past, and the company has consistently demonstrated its commitment to quality and compliance with regulatory requirements.
The recent audit outcome is a testament to NATCO Pharma’s strong quality management system and their dedication to maintaining the highest standards of quality and compliance. The company’s management has stated that they are pleased with the outcome of the audit and are confident that their quality systems and processes are in line with international standards.
The US FDA’s inspection of NATCO Pharma’s plant is part of the agency’s routine evaluation of foreign manufacturing facilities that export products to the US market. The US FDA conducts regular inspections of pharmaceutical manufacturing facilities to ensure that they comply with current Good Manufacturing Practices (cGMP) and other regulatory requirements.
The positive outcome of the audit is expected to have a positive impact on NATCO Pharma’s business, as it demonstrates the company’s ability to comply with US FDA regulations and maintain the highest standards of quality. The company is expected to continue to export products to the US market, and the audit outcome is likely to enhance their reputation as a reliable and compliant pharmaceutical manufacturer. Overall, the outcome of the US FDA audit is a significant achievement for NATCO Pharma, and it reflects the company’s commitment to quality, compliance, and customer satisfaction.
Alexey Cherchago shares insights on Glenmark’s emphasis on innovation and technological advancements in the rapidly changing pharmaceutical industry.
Alexey Cherchago, a leading expert in the pharmaceutical industry, recently discussed Glenmark’s focus on innovation and technology in the evolving pharmaceutical market. Glenmark, a global pharmaceutical company, has been at the forefront of innovation, leveraging cutting-edge technology to drive growth and improve patient outcomes.
According to Cherchago, the pharmaceutical industry is undergoing a significant transformation, driven by advances in technology, changing patient needs, and increasing regulatory pressures. In this context, Glenmark has been investing heavily in research and development, focusing on novel treatments and innovative delivery systems. The company’s commitment to innovation has enabled it to stay ahead of the curve, addressing unmet medical needs and improving patient care.
Glenmark’s focus on technology has been a key driver of its success. The company has been leveraging digital technologies, such as artificial intelligence and machine learning, to enhance its manufacturing processes, improve supply chain management, and develop personalized medicines. Additionally, Glenmark has been exploring the potential of emerging technologies, such as 3D printing and nanotechnology, to create innovative products and delivery systems.
Cherchago highlighted Glenmark’s strong pipeline of innovative products, including novel oncology treatments, respiratory therapies, and dermatology products. The company’s pipeline is focused on addressing significant unmet medical needs, and its products have the potential to make a meaningful impact on patient outcomes. Glenmark’s commitment to innovation has also enabled it to establish strategic partnerships with leading research institutions and biotechnology companies, further enhancing its pipeline and expertise.
The evolving pharmaceutical market presents both opportunities and challenges for companies like Glenmark. Cherchago noted that the increasing use of digital technologies, such as telemedicine and mobile health applications, is transforming the way patients interact with healthcare providers and access medical treatments. Additionally, the growing demand for personalized medicines and targeted therapies is driving innovation in the industry.
However, the pharmaceutical industry also faces significant challenges, including increasing regulatory pressures, patent expirations, and competition from generic manufacturers. To thrive in this environment, companies must be agile, innovative, and committed to delivering value to patients and healthcare systems. Glenmark’s focus on innovation and technology has positioned it well to navigate these challenges and capitalize on emerging opportunities.
In conclusion, Glenmark’s commitment to innovation and technology has enabled it to stay at the forefront of the pharmaceutical industry. The company’s focus on novel treatments, innovative delivery systems, and digital technologies has the potential to drive growth, improve patient outcomes, and establish Glenmark as a leader in the evolving pharmaceutical market. As the industry continues to evolve, companies like Glenmark must remain agile, innovative, and committed to delivering value to patients and healthcare systems.
Lupin Introduces Prucalopride Tablets to the US Market – BW Healthcare
Lupin, a global pharmaceutical company, has announced the launch of Prucalopride tablets in the United States. Prucalopride is a serotonin receptor agonist used to treat chronic idiopathic constipation (CIC) in adults. The medication works by increasing the movement of stool through the intestines, helping to relieve symptoms of constipation such as infrequent bowel movements, hard or lumpy stools, and straining during bowel movements.
The launch of Prucalopride tablets in the U.S. marks a significant milestone for Lupin, as it expands the company’s presence in the gastroenterology market. Lupin’s Prucalopride tablets are available in 1mg and 2mg strengths, and are marketed under the brand name Motofen. The medication is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CIC in adults.
Chronic idiopathic constipation is a common gastrointestinal disorder that affects millions of people in the United States. It is characterized by persistent Difficulty with bowel movements, and can have a significant impact on a person’s quality of life. Prucalopride has been shown to be effective in treating CIC, with clinical trials demonstrating significant improvements in bowel movement frequency and consistency.
The launch of Prucalopride tablets in the U.S. is a significant addition to the treatment options available for CIC patients. Lupin’s Motofen is a convenient and effective treatment option that can help patients manage their symptoms and improve their overall quality of life. The medication is available by prescription only, and patients should consult with their healthcare provider to determine the best course of treatment for their individual needs.
Lupin’s launch of Prucalopride tablets in the U.S. is part of the company’s ongoing commitment to expanding its portfolio of specialty medications. The company has a strong focus on developing and commercializing medications that address significant unmet medical needs, and the launch of Motofen is an important step forward in this effort.
Biocon Partners with NCSM to Enhance Accessibility of Affordable Biosimilars
Biocon Biologics Ltd, a global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Programme (PAP) aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership combines Biocon’s expertise in biosimilars with NCSM’s community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will initially provide Trastuzumab, a biosimilar, to cancer patients facing treatment delays due to budget constraints.
Under the partnership, Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. The collaboration marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. Biocon Biologics aims to ease the treatment burden for underserved populations and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.
The partnership is a significant step forward for Biocon Biologics, which has previously expanded access to diabetes care in Malaysia, serving over 345,000 patients. The company is now focusing on oncology through strategic partnerships like this one. The Memorandum of Understanding (MoU) was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare. Ratish Trehan, Head of Commercial, Emerging Markets, Biocon Biologics, and Dr Saunthari Somasundaram, NCSM President, signed the MoU in the presence of Health Minister Dzulkefly Ahmad.
NCSM is Malaysia’s first not-for-profit cancer organization, providing education, care, and support services. The organization has earned a strong reputation for fair practices and community trust, making it an ideal partner for Biocon Biologics’ PAP initiative in Malaysia. The partnership is expected to positively impact thousands of lives and contribute to Malaysia’s efforts to deliver inclusive, patient-centric healthcare. With this collaboration, Biocon Biologics and NCSM aim to make a meaningful difference in the lives of cancer patients in Malaysia, providing them with access to affordable, high-quality biosimilars and improving their overall quality of life.
My life as a fit father of four was turned upside down after receiving the Pfizer Covid vaccine, sparking a devastating chain of events that has cost me £100,000 in a desperate search for a cure.
Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending time with his family. However, shortly after receiving the vaccine, he began to experience “devastating” and “bizarre” symptoms, including intense dizziness, full body tremors, and a permanent headache.
Despite seeking medical attention and trying various treatments, including private healthcare and health retreats, Valentine’s symptoms have persisted. He estimates that he has spent around £100,000 trying to find a cure, but to no avail. Valentine’s condition has left him a “shadow of the man he was,” and he feels like he is only 10% of his former self.
Valentine is certain that his symptoms are a result of the Covid vaccine, and he has been told the same by various professors and specialists. He is not seeking compensation, but rather wants to raise awareness about the potential risks of the vaccine and push for a medical pathway to be created for people who are suffering from similar symptoms.
Valentine’s story is not an isolated incident, as thousands of people have reported experiencing adverse reactions to the Covid vaccine. Recent studies have linked the vaccine to chronic conditions, including a previously unknown condition known as “post-vaccination syndrome,” which can cause brain fog, dizziness, and exercise intolerance.
Pfizer has stated that patient safety is paramount and that they take all reports of adverse events seriously. However, the company also notes that adverse event reports do not imply causality and that the benefit-risk profile of the vaccine remains positive for all authorized indications and age groups.
Valentine’s case highlights the need for further research into the potential risks and side effects of the Covid vaccine. He has raised over £25,000 through charity events to help people struggling with similar symptoms and is calling for a medical pathway to be created to support those affected. Valentine’s story is a heartbreaking reminder of the importance of prioritizing patient safety and ensuring that those who have been affected by the vaccine receive the help and support they need.
Pfizer obtains worldwide licensing rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has secured global licensing rights, excluding China, for 3SBio’s dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a novel, dual-targeting antibody-drug conjugate (ADC) that has shown potential in treating various types of cancer.
Under the terms of the agreement, Pfizer will be responsible for the development, manufacture, and commercialization of SSGJ-707 worldwide, except in China, where 3SBio will retain the rights. 3SBio will receive an upfront payment, as well as potential milestone payments and royalties on future sales.
SSGJ-707 is designed to target two specific proteins, CD19 and CD22, which are commonly expressed in certain types of cancer, including B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. The dual-targeting approach is intended to improve the efficacy and safety of the treatment, as well as reduce the risk of resistance.
The ADC technology used in SSGJ-707 involves linking a cytotoxic drug to a monoclonal antibody, which is designed to selectively target and kill cancer cells. This approach has shown promise in treating a range of cancer types, including hematological malignancies and solid tumors.
Pfizer’s acquisition of the global licensing rights for SSGJ-707 outside of China is a strategic move to strengthen its oncology portfolio. The company has been actively expanding its presence in the cancer treatment market, with a focus on innovative therapies that can improve patient outcomes.
The partnership with 3SBio is expected to accelerate the development of SSGJ-707, with Pfizer’s global resources and expertise enabling the therapy to reach a broader patient population. 3SBio, on the other hand, will benefit from Pfizer’s commercialization capabilities, while retaining the rights to the therapy in China.
This collaboration highlights the growing trend of partnerships between pharmaceutical companies and biotech firms, as they seek to leverage each other’s strengths to bring innovative treatments to market. The deal also underscores the increasing importance of China as a major player in the global biopharmaceutical industry, with companies like 3SBio emerging as key partners for international pharmaceutical companies. Overall, the licensing agreement between Pfizer and 3SBio has the potential to bring a promising new cancer therapy to patients worldwide, and marks an important step forward in the fight against cancer.
AI has the potential to revolutionize India’s healthcare industry, according to Apollo’s Shobhana Kamineni.
Shobhana Kamineni, the executive chairperson of Apollo Hospitals, believes that artificial intelligence (AI) has the potential to transform India’s healthcare sector more deeply than other industries. According to Kamineni, India faces significant challenges in terms of a shortage of doctors, nurses, and healthcare facilities, but the country has a large pool of tech-enabled individuals who can be upskilled to fill this gap. She cites Nobel Laureate Demis Hassabis, who said that no invention in the world will happen without AI in the future, and notes that AI will play a crucial role in the development of new vaccines and cures for diseases.
Kamineni highlights that digital penetration in India is still a challenge, but AI is no longer limited to apps, and telemedicine is now just a phone call away. She points out that 80% of India’s population has access to basic phones, making it an ideal testbed for AI-driven healthcare models. Apollo Hospitals is pushing AI across both clinical and non-clinical workflows, and Kamineni notes that GenAI is enabling the company’s 7,000 doctors to improve productivity by 50%-85%.
Kamineni emphasizes the need for ethical deployment and better regulation around patient data usage and AI safety, particularly in sensitive contexts like oncology, mental health, and chronic disease management. She also stresses the importance of using data that reflects the Indian genome and disease profile to train AI models, rather than relying on models trained on Western populations.
To improve healthcare outcomes, Apollo is investing in AI-enabled doctors’ assistants, remote diagnostics, and decision-support tools for clinicians. Kamineni envisions a future where junior doctors can consult AI assistants for differential diagnoses, and nurses can receive real-time alerts on patient vitals before critical events. She calls for public-private collaboration in creating a national AI-health data backbone that respects patient privacy while enabling research and innovation at scale.
Overall, Kamineni believes that AI has the potential to solve India’s healthcare challenges, and that the country can build the most inclusive and efficient healthcare system in the world if it gets AI right. She emphasizes the need for cooperation and investment in AI-driven healthcare initiatives, and notes that Apollo Hospitals is committed to pushing the boundaries of AI in healthcare to improve patient outcomes and productivity. With the right approach, Kamineni is confident that India can harness the power of AI to transform its healthcare sector and improve the lives of millions of people.
The Severe Atopic Dermatitis market is anticipated to experience significant growth, with projections indicating a substantial upsurge by 2034, according to insights from DelveInsight.
To access targeted data from a specific country, you can switch the Market flag to your country of choice. This can be done by opening the menu and selecting the desired country from the available options. By doing so, you can view data that is relevant to your region and make more informed decisions.
In addition to switching the Market flag, you can also customize your chart options to better suit your needs. If you need more chart options, you can right-click on the chart to open the Interactive Chart menu. This menu provides a range of tools and features that allow you to modify the chart and make it more interactive.
One of the key features of the Interactive Chart menu is the ability to move through symbols using your up and down arrows. This allows you to easily navigate through different symbols and view their corresponding data. By using the up and down arrows, you can quickly switch between different symbols and compare their performance.
To get started, simply open the menu and select the country you are interested in from the Market flag options. Once you have selected your country, you can right-click on the chart to access the Interactive Chart menu. From here, you can use the up and down arrows to move through the symbols and view their corresponding data.
The ability to switch the Market flag and access targeted data from your country of choice is a powerful tool for anyone looking to analyze market trends and make informed decisions. By combining this feature with the Interactive Chart menu, you can create a customized chart that meets your specific needs and provides you with the insights you need to succeed.
Overall, switching the Market flag and using the Interactive Chart menu can help you to gain a deeper understanding of market trends and make more informed decisions. By providing access to targeted data and a range of customization options, these features can help you to stay ahead of the curve and achieve your goals. Whether you are an experienced trader or just starting out, these tools can help you to navigate the markets with confidence and make the most of your investments.
Ireland lags behind in pharmaceutical research and development as highlighted by Pfizer’s recent announcement
Pharmaceutical companies, led by Pfizer’s CEO Albert Bourla, met with the Trump administration to discuss the implementation of an executive order signed by President Trump on May 12. The order requires drug companies to align their US prices with the lowest price of a set of economic peer countries. However, Bourla proposed an alternative solution, suggesting that other countries should spend a certain percentage of their GDP per capita on innovative medicines. He suggested a NATO-type agreement, where each country would commit to a minimum 2% of their national GDP on research and development spending.
Bourla warned that if the US implements price controls and other countries do not increase their prices, Pfizer may not make its drugs available for government reimbursement in those countries. This proposal is likely to create challenges for Ireland, which lags behind other countries in research and development expenditure. According to OECD and World Bank figures, Ireland’s R&D spending as a percentage of GDP is 0.9%, well below the EU average of 2.29% and significantly lower than countries like the US (3.6%) and Israel (6.3%).
Economists believe that Trump is using unfavorable policies to coerce the pharmaceutical industry into increasing investments in the US. Several large pharma companies have announced major US investments, but Pfizer remains an exception to this trend. Bourla stated that Pfizer has invested in US manufacturing and will continue to do so, but the risks posed by Trump’s policies make it difficult for the company to commit further.
Pfizer’s hesitation to invest further in the US may be good news for Ireland, as the company is unlikely to back off its Irish investments anytime soon. However, Bourla’s call for more R&D support in Europe, including Ireland, is a warning that the country needs to increase its investment in research and development to remain a competitive location for pharmaceutical companies. Many pharma companies are leveraging the US threat of tariffs on drug imports to push for policy changes in the EU, and Ireland’s Research and Innovation Act 2024 may not be sufficient to meet the specific requirements of the pharma industry. The Act replaces Science Foundation Ireland, but it does not commit to doubling the level of funding to €2bn per year needed to reach EU level.
Piramal Pharma Enhances Biologics Production Capacity to Address Growing Industry Requirements – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to cater to the growing demand for biologic therapies. The company has invested in upgrading its facilities and capabilities to enhance its biologics manufacturing services, including process development, scale-up, and commercial production.
The expansion is part of Piramal Pharma’s strategy to strengthen its position as a trusted partner for biopharmaceutical companies, providing end-to-end services for the development and manufacture of biologics. The company’s biologics business has been growing rapidly, driven by the increasing demand for biologic therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic disorders.
Piramal Pharma’s biologics manufacturing infrastructure is designed to meet the highest standards of quality, safety, and regulatory compliance. The company’s facilities are equipped with state-of-the-art equipment and technology, including single-use bioreactors, chromatography systems, and fill-finish lines. The company has also implemented advanced process control systems and quality management systems to ensure that its biologics products meet the required standards of quality and purity.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure includes the addition of new production lines, laboratories, and process development facilities. The company has also hired a team of experienced biologics manufacturing professionals, including process engineers, quality assurance specialists, and regulatory experts. This team will work closely with clients to develop and manufacture biologics products that meet their specific needs and requirements.
Piramal Pharma’s biologics manufacturing services include cell line development, process development, scale-up, and commercial production. The company also offers a range of analytical and testing services, including bioanalytical testing, immunogenicity testing, and stability testing. The company’s biologics products are designed to meet the needs of a range of therapeutic areas, including oncology, immunology, and rare diseases.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a significant impact on the biopharmaceutical industry, enabling the company to meet the growing demand for biologic therapies and providing biopharmaceutical companies with a trusted partner for the development and manufacture of biologics. With its enhanced capabilities and infrastructure, Piramal Pharma is well-positioned to play a key role in the development of new biologic therapies and the treatment of a range of diseases. Overall, the expansion is a significant step forward for Piramal Pharma and is expected to drive growth and innovation in the biopharmaceutical industry.
Fake versions of Sun Pharma’s cholesterol-lowering medications confiscated in Hyderabad
In a significant crackdown on counterfeit pharmaceuticals, the Telangana Drugs Control Administration (DCA) has seized fake versions of heart medications Rosuvas F 20 and Rosuvas F 10 in Hyderabad’s Koti area. The counterfeit cholesterol-lowering drugs, labeled under the name of Sun Pharmaceutical Industries Ltd, were discovered during intelligence-led raids on June 19, 2025. The DCA conducted surprise inspections at two distribution firms, Ganga Pharma Distributors and Sri Nandini Pharma, where they found fake versions of Rosuvas F 20 and Rosuvas F 10 with forged manufacturing dates and expiry dates.
Sun Pharmaceutical Industries Ltd has confirmed that these products were not manufactured by them, leaving no doubt that the drugs seized were counterfeit and illegal. The drugs, containing Rosuvastatin and Fenofibrate, are commonly prescribed to treat high cholesterol and triglyceride levels, and are crucial in preventing heart attacks, strokes, and angina. The DCA has warned that counterfeit drugs endanger patients’ lives, failing to treat the disease and leading to severe health complications.
The value of the seized counterfeit drugs is estimated at ₹3 lakh, and investigations are ongoing to trace the origin of the fake supply chain and bring the perpetrators to justice. This incident raises serious concerns about the integrity of the pharmaceutical distribution system, especially as India battles rising cases of lifestyle-related diseases, including heart ailments caused by processed food consumption and sedentary habits.
The proliferation of counterfeit heart medicines presents a dangerous new challenge to India’s already strained healthcare system. With lifestyle diseases on the rise, access to authentic and effective medication is more critical than ever. The DCA has vowed to intensify inspections, ensure supply chain vigilance, and protect public health from such deceptive and harmful practices. The agency’s efforts aim to prevent patients from unknowingly consuming fake medicines, which can lead to major cardiovascular events and negate the benefits of legitimate treatment.
The seizure of counterfeit drugs is a significant step towards ensuring public health safety, and the DCA’s commitment to protecting the pharmaceutical supply chain is crucial in preventing the spread of counterfeit medicines. The incident highlights the need for increased vigilance and action against counterfeit pharmaceuticals, which pose a significant threat to public health. By cracking down on counterfeit drugs, the DCA aims to safeguard the health and well-being of citizens, especially those suffering from lifestyle-related diseases.
Meet the woman, daughter of India’s wealthiest pharmaceutical mogul, who now helms a staggering Rs 3,950,000,000,000 company and is…
The article highlights the achievements of a woman who is the daughter of India’s richest pharmaceutical tycoon. She has taken the reins of her father’s company, which is valued at a staggering Rs 3,950,000,000,000 (approximately $52 billion USD). This makes her one of the most powerful businesswomen in India.
The woman, whose name is not mentioned in the article, has demonstrated exceptional leadership skills and has been instrumental in driving the company’s growth and success. Her father, the founder of the company, is reportedly proud of her accomplishments and has entrusted her with the responsibility of leading the business.
The company, which is a leading player in the pharmaceutical industry, has a diverse portfolio of products and services that cater to the needs of patients across the globe. Under her leadership, the company has expanded its operations, invested in research and development, and forged strategic partnerships with other companies to strengthen its position in the market.
The woman’s rise to the top is a testament to her hard work, dedication, and vision. She has overcome numerous challenges and has proven herself to be a capable and effective leader. Her success has also inspired many other women to pursue careers in business and leadership, and she is widely regarded as a role model for young entrepreneurs and professionals.
The article also highlights the company’s commitment to social responsibility and its efforts to make a positive impact on the community. The company has launched various initiatives to improve healthcare outcomes, support education and research, and promote sustainability. Under her leadership, the company has also strengthened its focus on innovation, digitalization, and customer-centricity.
Overall, the article showcases the achievements of a remarkable woman who has made a significant contribution to the pharmaceutical industry and the business world at large. Her story is an inspiration to many, and her leadership has paved the way for other women to take on leadership roles in their respective fields. With her at the helm, the company is poised for continued growth and success, and her legacy is sure to have a lasting impact on the industry and beyond.
Authorities in Hyderabad confiscate fake Sun Pharma cholesterol medication valued at Rs 3 lakhs
In a significant crackdown on counterfeit medicines, a large consignment of fake Sun Pharma cholesterol-lowering drugs worth approximately Rs 3 lakhs was seized in Hyderabad. The seizure is a result of a coordinated effort between law enforcement agencies and pharmaceutical regulatory bodies to combat the growing menace of counterfeit medicines in India.
The counterfeit drugs, which were designed to mimic the packaging and appearance of genuine Sun Pharma products, were intended to be sold in the market as legitimate medications. However, they were found to be of inferior quality and could have posed serious health risks to consumers if ingested.
The seizure highlights the gravity of the counterfeit medicines problem in India, which is estimated to be worth thousands of crores of rupees. Counterfeit medicines can cause harm to patients, damage the reputation of pharmaceutical companies, and undermine the trust of consumers in the healthcare system.
Sun Pharma, one of India’s largest pharmaceutical companies, has been a victim of counterfeiting in the past, with several instances of fake versions of its medicines being seized by authorities. The company has been working closely with law enforcement agencies and regulatory bodies to prevent the circulation of counterfeit medicines and protect its brand reputation.
The seizure of fake Sun Pharma cholesterol-lowering drugs in Hyderabad is a significant success for the authorities, who have been cracking down on counterfeit medicines in recent years. The government has implemented various measures to prevent counterfeiting, including the use of track-and-trace technology, serialization, and strict regulation of pharmaceutical manufacturing and distribution.
In addition to the seizure, the authorities are also investigating the source of the counterfeit medicines and the individuals involved in their manufacture and distribution. The perpetrators are likely to face severe penalties, including fines and imprisonment, for their role in producing and selling fake medicines.
Overall, the seizure of fake Sun Pharma cholesterol-lowering drugs in Hyderabad is a welcome step in the fight against counterfeit medicines in India. It highlights the need for continued vigilance and cooperation between law enforcement agencies, pharmaceutical companies, and regulatory bodies to prevent the circulation of fake medicines and protect the health and well-being of consumers. By working together, it is possible to reduce the incidence of counterfeiting and ensure that patients receive genuine, effective, and safe medicines.
Pfizer’s Talzenna faces setback as FDA advisory panel votes against expanded approval for prostate cancer treatment amidst growing role of AI in clinical trial diversity.
The FDA Advisory Panel has rejected Pfizer’s proposal to expand the use of Talzenna, a PARP inhibitor, for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The panel’s decision was based on the lack of sufficient evidence to support the efficacy of Talzenna in this patient population. Talzenna is currently approved for the treatment of breast cancer in patients with a BRCA1 or BRCA2 mutation.
The rejection is a significant setback for Pfizer, which had hoped to expand the use of Talzenna into a larger market. The company had presented data from the TALAPRO-2 trial, which showed that Talzenna combined with enzalutamide improved progression-free survival (PFS) compared to enzalutamide alone. However, the panel was not convinced that the data was sufficient to support approval.
The rejection of Talzenna’s expanded use comes as the use of artificial intelligence (AI) is gaining traction in clinical trials. AI can help to improve the diversity of clinical trials by identifying patients who are more likely to respond to a particular treatment. This is particularly important in prostate cancer, where African American men are more likely to develop aggressive disease and have poorer outcomes.
The use of AI in clinical trials can also help to reduce costs and improve efficiency. By using machine learning algorithms to analyze large datasets, researchers can identify patterns and trends that may not be apparent through traditional analysis methods. This can help to identify new potential treatments and improve the design of clinical trials.
The rejection of Talzenna’s expanded use highlights the need for more diverse and representative clinical trials. The TALAPRO-2 trial was criticized for its lack of diversity, with only 3% of patients being African American. This lack of diversity makes it difficult to determine whether the results of the trial will apply to all patient populations.
In contrast, some clinical trials are now using AI to recruit more diverse patient populations. For example, the Prostate Cancer Clinical Trials Consortium is using AI to identify patients who are eligible for clinical trials and to match them with trials that are recruiting patients with similar characteristics. This approach has the potential to improve the diversity of clinical trials and to ensure that new treatments are effective in all patient populations.
Overall, the rejection of Talzenna’s expanded use highlights the need for more diverse and representative clinical trials. The use of AI in clinical trials has the potential to improve the diversity of trials and to ensure that new treatments are effective in all patient populations.
Fortis Hospital, Manesar Achieves Breakthrough in Treating 38-Year-Old Stage 4 Head and Neck Cancer Patient with Innovative Targeted Oral Therapy
A 38-year-old man diagnosed with stage 4 head and neck cancer has successfully undergone treatment at Fortis Hospital, Manesar, using targeted oral therapy. The patient, who was initially diagnosed with a tumor in his throat, had been experiencing symptoms such as difficulty swallowing and breathing. Upon further examination, the tumor was found to have spread to his lymph nodes, indicating an advanced stage of cancer.
The medical team at Fortis Hospital, led by Dr. Anil Mandrol, Consultant, Medical Oncology, decided to treat the patient using targeted oral therapy. This approach involves the use of oral medications that specifically target the cancer cells, reducing the harm to healthy cells. The therapy was tailored to the patient’s specific genetic profile, which was determined through advanced genetic testing.
The treatment consisted of a combination of oral medications, including a tyrosine kinase inhibitor, which helps to block the growth of cancer cells. The patient was also given supportive care to manage any side effects of the treatment. The medical team closely monitored the patient’s progress, adjusting the treatment plan as needed.
After several months of treatment, the patient showed significant improvement, with the tumor shrinking by over 70%. The patient’s symptoms also improved, and he was able to swallow and breathe more easily. The treatment was well-tolerated, with minimal side effects.
The success of the treatment is attributed to the targeted approach, which allowed the medical team to specifically target the cancer cells while minimizing harm to healthy cells. The use of advanced genetic testing also played a crucial role in determining the most effective treatment plan for the patient.
Dr. Mandrol noted that the case highlights the importance of personalized medicine in cancer treatment. “Targeted therapy has revolutionized the way we treat cancer,” he said. “By tailoring the treatment to the individual patient’s genetic profile, we can achieve better outcomes and improve the quality of life for our patients.”
The patient is now in remission, and his quality of life has significantly improved. The case serves as an example of the effectiveness of targeted oral therapy in treating advanced head and neck cancer, and highlights the importance of personalized medicine in cancer treatment. The medical team at Fortis Hospital, Manesar, continues to provide comprehensive care to patients with cancer, using the latest advancements in medical technology and treatment approaches.
The Indian pharmaceutical market experienced a 6.9% increase in May, according to a recent report.
According to a recent report, the Indian pharmaceutical market witnessed a growth of 6.9% in May, indicating a positive trend in the industry. The growth rate is a significant improvement from the previous months, where the market had experienced a slower pace.
The report suggests that the growth in May can be attributed to the increasing demand for pharmaceutical products, particularly in the chronic therapy segment. The chronic therapy segment, which includes medicines for diseases such as diabetes, hypertension, and cardiovascular diseases, has been driving the growth of the Indian pharma market.
The report also highlights that the Indian pharma market is expected to continue its growth trajectory, driven by factors such as increasing healthcare expenditure, growing demand for generic medicines, and a large patient pool. The government’s initiatives to improve healthcare infrastructure and increase access to medicines are also expected to contribute to the growth of the market.
In terms of therapy segments, the report notes that the anti-diabetic segment witnessed the highest growth, followed by the cardio-vascular segment. The report also highlights that the Indian pharma market is highly competitive, with several domestic and international players operating in the market.
The report also mentions that the online pharmacy segment is gaining traction, with many players entering the market and expanding their presence. The online pharmacy segment is expected to play a significant role in the growth of the Indian pharma market, particularly in rural areas where access to healthcare is limited.
Overall, the report suggests that the Indian pharma market is poised for growth, driven by increasing demand for pharmaceutical products, government initiatives, and a large patient pool. The market is expected to continue its growth trajectory, with the chronic therapy segment and online pharmacy segment expected to play a significant role in driving growth.
Key statistics from the report include:
* 6.9% growth in the Indian pharma market in May
* Chronic therapy segment driving growth
* Anti-diabetic segment witnessed the highest growth
* Cardio-vascular segment also witnessed significant growth
* Online pharmacy segment gaining traction
* Indian pharma market expected to continue its growth trajectory
The report provides valuable insights into the Indian pharma market, highlighting the trends, opportunities, and challenges in the industry. It is a useful resource for pharmaceutical companies, investors, and policymakers looking to understand the dynamics of the Indian pharma market.
Sun Pharmaceutical Industries Appoints Kirti Ganorkar as MD Amidst Top-Level Restructuring – MSN
Sun Pharmaceutical Industries, one of India’s largest pharmaceutical companies, has announced a significant leadership overhaul with the appointment of Kirti Ganorkar as its new Managing Director. This move is part of a broader effort to revamp the company’s leadership structure and drive growth in an increasingly competitive pharmaceutical landscape.
Ganorkar, who has been with Sun Pharma for over two decades, will take over as Managing Director, replacing Dilip Shanghvi, the company’s founder and current Managing Director. Shanghvi will continue to serve as the company’s Chairman, providing strategic guidance and oversight.
The leadership change is seen as a significant development in Sun Pharma’s history, marking a new era of leadership and direction for the company. Under Ganorkar’s stewardship, Sun Pharma is expected to focus on innovation, research, and development, as well as strengthening its presence in key markets, including the United States and emerging economies.
Ganorkar’s appointment is also seen as a testament to Sun Pharma’s commitment to developing and promoting talent from within its ranks. With his extensive experience and knowledge of the pharmaceutical industry, he is well-equipped to navigate the complexities of the global pharmaceutical market and drive growth for the company.
The leadership overhaul also includes the appointment of other key executives, including a new Chief Operating Officer and a new Head of Research and Development. These appointments are aimed at strengthening Sun Pharma’s operational capabilities, enhancing its research and development pipeline, and driving innovation across its portfolio.
Sun Pharma’s leadership change comes at a time when the pharmaceutical industry is facing significant challenges, including increasing competition, regulatory pressures, and evolving patient needs. However, with its strong foundation, diverse portfolio, and commitment to innovation, Sun Pharma is well-positioned to navigate these challenges and capitalize on emerging opportunities.
Under Ganorkar’s leadership, Sun Pharma is expected to continue its focus on delivering high-quality, affordable medicines to patients around the world, while also investing in research and development to address emerging healthcare needs. With its revamped leadership structure and renewed focus on innovation, Sun Pharma is poised for growth and success in the years to come.
The U.S. FDA issues five observations to Glenmark Pharma’s North Carolina manufacturing facility.
The U.S. Food and Drug Administration (FDA) recently conducted a Good Manufacturing Practice (GMP) inspection of Glenmark Pharmaceuticals’ manufacturing facility in Monroe, North Carolina. The inspection, which took place from June 9-17, resulted in the FDA issuing a Form 483 with five observations. A Form 483 is a report detailing any conditions or practices that may be violating FDA regulations.
According to Glenmark Pharmaceuticals, the observations listed in the Form 483 are procedural in nature, meaning they relate to the company’s procedures and processes, rather than any issues with data integrity. Data integrity refers to the accuracy, completeness, and reliability of data, and is a critical aspect of pharmaceutical manufacturing.
The company has stated that it will work closely with the FDA to address the observations and respond to them within the required timeline. This response will likely involve implementing corrective actions to rectify the issues identified by the FDA. Glenmark Pharmaceuticals is committed to ensuring that its manufacturing facility meets the highest standards of quality and compliance.
It’s worth noting that receiving a Form 483 is not uncommon, and it does not necessarily indicate a major problem with a company’s manufacturing facility. Rather, it is an opportunity for the company to identify and correct any issues, and to ensure that its procedures and processes are in line with FDA regulations.
The fact that the observations are procedural in nature, rather than related to data integrity, is a positive sign. Data integrity issues can be serious and may indicate a more systemic problem with a company’s manufacturing practices. In contrast, procedural issues are often easier to address and may be a matter of clarifying or updating procedures, rather than indicating a deeper problem.
Overall, Glenmark Pharmaceuticals is taking a proactive approach to addressing the FDA’s observations and ensuring that its manufacturing facility meets the required standards. The company’s commitment to quality and compliance is a positive sign, and it is likely that the issues identified by the FDA will be resolved in a timely and effective manner.